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1. Introduction 
1.1. Deferiprone 
Deferiprone (CP20), under the chemical name of 1,2-dimethyl-3-hydroxypyrid-4-one (Fig. 1), 
is the first oral active iron-chelator. CP20 was introduced by Hider and coworkers in 1982 and 
approved for clinical use in India in 1995. After that, in 2000, the European Medical Agency 
(EMA) approved CP20 for treatment of iron overload syndrome with comorbid β-thalassemia 
caused by regular blood transfusions [1]. CP20 is only one derivative of 3-hydroxypyridin-4-
one (HPs) and has been approved after undergoing extensive chemical, biological, and phar-
macological investigation [2–4]. Therefore, CP20 development and administration to patients 
before fulfilling all of the formal toxicological evaluations obtained from animal data is an unu-
sual pattern in drug development [5]. Although three decades passed before the drug was 
approved internationally under the trade name (FerriproxTM), the Food and Drug Administration 
(FDA) approved CP20 in 2011 after extensive reviews in which approval was based on reduc-
tion of serum ferritin levels without observed treatment benefits, such as symptom improve-
ment or an increase in survival time [6]. Moreover, CP20 is effective in reducing cardiac iron 
more than other approved iron chelators, including deferoxamine (DFO) and deferasirox (DFX) 
[7,8].  
 
 
Fig.1. Deferiprone chemical structure. 
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1.1.1.  Deferiprone chemistry 
CP20 is a bidentate iron chelator which consisted of alpha hydroxyketone (O, O) chelating 
groups with high binding capacity. Although HPs were extensively studied as iron chelators, 3-
hydroxypyridin-4-one (3,4 HP) derivatives exhibited significant chelation effects against triva-
lent hard metal ions (such as Fe3+, Al3+, and Ga3+) more than against soft divalent metal ions, 
such as Zn2+ and Cu2+ [3,9,10]. This behavior is favored in order to achieve relative selectivity 
for binding with essential Fe3+ ions without disturbing the physiological levels of the other es-
sential metal ions. Hence, these derivatives are successful in treatment of iron overload, which 
is considered the most prevalent clinical metal overload situation that requires the use of iron 
chelators [11]. Furthermore, CP20 offers high electron density in the presence of two adjacent 
functional groups in which the basic properties of the hydroxyl group (pKa ~ 9.8) and acidic 
properties of the carbonyl group (pKa ~ 3.7) make the drug molecule neutral under physiologi-
cal pH [11,12]. CP20 binds with Fe3+ under the physiological conditions to form an Fe (CP20)3 
complex in a 1:3 binding ratio in which each Fe3+ ion require three molecules of CP20 to form 
a stable neutral complex as shown in Fig. 2.  
 
 
  Fig. 2. The chemical reaction scheme for CP20 with Fe3+ to form 1:3 metal-chelate  
              complex. 
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The resulting complexes in 1:3 binding ratios are stable under wide pH ranges as shown in 
Fig. 3. In addition, incomplete 1:2 complexes have been observed in dilute solutions <10-6 M 
[12,13]
 
Fig.3. Distribution curve of [Fe(CP20)n] complexes over different pH range [12]. 
The binding of CP20 with Fe3+ is higher than other iron chelators and has an estimated binding 
constant of logβ ~ 35, which is five orders higher in magnitude than DFO (logβ ~ 30) and eight 
magnitudes higher than DFX (logβ ~ 27) [12–14]. However, CP20 presents less chelation effi-
ciency than the other iron chelators according to the pFe parameter, which is defined as the 
negative logarithm of the concentration of free Fe3+ in solution at pH 7.4 in which the total Fe3+ 
concentration equals 1 μM, and the total chelator concentration equals 10 μM. The estimated 
pFe values for iron chelators can be listed in the following order: CP20 pFe ~ 20 <DFX pFe ~ 
22 <DFO pFe ~ 27. The pFe values of an effective iron chelator should be ≥20 in order to 
mobilize iron from transferrin (Tf), which is the main iron storage protein [14,15] although the 
pFe value takes ligand protonation, denticity, and stoichiometry into account whenever meas-
uring the concentration of free metal ions in solution. However, the in vivo drug behavior is 
quite different from that in solution. There are many factors, including plasma ionic strength, 
presence of other natural chelators (such as citrate and carboxylate), and physiological tem-
perature that might influence binding events, and these factors are not addressed in the pFe 
definition. In addition, the iron concentration that is estimated according to the pFe definition is 
elevated in pathological situations and predicted to be higher than 10-6 M. Nevertheless, the 
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binding constant and pFe parameters at equilibrium can reflect the efficacy of different iron 
chelators [1,3,12,13,15]. 
1.1.2. Deferiprone pharmacology  
The pharmacology of iron chelators correlates with these drugs’ capacities to sequester non-
transferrin bound iron within the targeted sites since iron is vital for several biosynthetic and 
transport pathways due to its characteristic redox chemistry. However, iron overload is a seri-
ous health problem in many diseases, such as thalassemia and sickle cell anemia, due to 
genetic defect in adequate hemoglobin (Hb) synthesis. Patients with these conditions need 
regular blood transfusions since iron is deposited and accumulate in different body organs, 
such as liver, spleen, heart, brain, and kidney and can lead to organ dysfunction [14,16]. 
Herein, chelation therapy is the only strategy for removing excess iron from the body in the 
absence of the normal physiological mechanism. CP20 is a selective iron chelator that binds 
to Fe3+ to form a complex in a 1:3 binding ratio as shown in Fig. 3. Iron removal via CP20 
occurs at the cellular level in which there are two iron deposition pathways for preserving Fe3+ 
in solubilized form and inhibiting metal precipitation in the cell: (1) via transferrin as an iron 
bound form or (2) non-transferrin bound iron, which is bound to low-molecular-weight chelators, 
such as intracellular or extracellular citrate or carboxylate (Fig. 4). 
Although CP20 is administered in relatively high doses (~ 3.5 g/ day), first pass metabolism 
deactivates about 85% of CP20 via conjugation with O-glucuronide [17]. However, other phar-
macokinetic properties such as half-life (t1/2 ~ 1.9h), volume distribution (VD ~ 1.6 L/Kg), and 
plasma protein binding (< 10%) are optimal for clinical use as iron chelator in order to avoid 
drug accumulation in the body fats, especially in the central nervous system during long-term 
use [5,6,18]. 
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Fig. 4. Schematic illustration of CP20 Mechanism of action where, (A) indicate the che-
lation of non-transferrin bound iron, (B) indicate the chelation effect to Fe from 
low molecular weight chelators outside the cell, (C), (D), (E), represent the che-
lation effect for intracellular iron pool [14]. 
 
The side effects of CP20 that have been reported include gastrointestinal abnormalities, such 
as nausea and vomiting; however, agranulocytosis which was shown to have fatal side effects, 
has also been reported in about 1.7% of patients who received CP20. The severe drop in the 
count of white blood cells, especially neutrophils, is concomitant with CP20 administration. This 
side effect can be resolved with discontinuation of CP20, but the mechanism of CP20-associ-
ated agranulocytosis is still unknown [5,6]. Furthermore, arthritis, arthralgia, and Zn-depletion 
have been reported to a lesser extent as side effects resulting from CP20 treatment. Generally, 
CP20’s safety and efficacy is still questionable due to its drug behavior in biological systems; 
for example, the Fenton reaction can occur due to dissociation of the Fe(CP20)3 complex [19]. 
Moreover, it is still not known whether CP20 is secreted into breast milk, especially with respect 
to evaluating the safety of CP20 during the lactation. The FDA and EMA have stated: “It is not 
known whether deferiprone is excreted in human milk.” [5,6]. CP20, similar to many drugs, 
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might be secreted in breast milk as a protein-bound fraction, in which case it would be harmful 
to a baby’s growth and general health. 
In contrast to the previous concerns, CP20 is still promising as an iron chelator in several 
clinical situations other than iron overload syndrome. These situations include cancers, fungal 
and viral infections, and renal insufficiency. Although the study of iron chelators as antitumor 
agents is still in its infancy, there are several trials describing the beneficial use of iron chelators 
in treatment-specific types of cancers and correlating the findings with iron chelation effects at 
the cellular level [20]. Overexpression of transferrin (Tf) receptors has been demonstrated in 
numerous types of cancers, such as leukemia, lymphoma, and breast and prostate cancers; 
thereby, it clarifies the substantial role of iron in DNA synthesis and repair, which is catalyzed 
by a key enzyme known as ribonucleotide reductase. Iron chelation therapy can help to slow 
the overproduction of these enzymes [17]. Moreover, CP20 has been investigated for its effects 
on inhibiting prostate cancer proliferation via its capability to inhibit the mitochondrial enzyme 
known as mitochondrial aconitase. This enzyme is sensitive to cellular iron levels and depletion 
of mitochondrial iron can help to inactivate this enzyme [21]. Additionally, CP20 has been 
shown to exhibit a blocking effect on eukaryotic initiation factor 5A (eIF5A), which is involved 
in protein synthesis; overexpression of this initiation factor has been shown to be correlated 
with cancer [22]. In addition, CP20 as an iron chelator is beneficial for neurodegenerative dis-
eases such as Parkinson’s and Alzheimer’s diseases (PD and AD, respectively). The role of 
iron overload has been well defined in disease development through its association with oxi-
dative stress increase [23,24]. Hence, CP20 is presently in phase II clinical trials for treatment 
of PD [25]. Moreover, CP20 has been reported to be beneficial in treatment of Friedreich’s 
ataxia (FA) [25,26] and diabetic and non-diabetic nephropathies [27]. CP20 also exhibits potent 
antifungal activity [28,29], and has been proven to induce apoptosis in HIV-infected cell lines 
through inhibition of deoxyhypusyl hydroxylase, an enzyme involved in the final step of the 
amino acid hypusine that found in eIF5A protein [30]. CP20 as HPs lead structure, is still prom-
ising for several clinical uses as illustrated in Fig. 5.   
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Fig.5. HPs as lead pharmaceutical for different targeted functions [11]. 
 
1.1.3. Deferiprone binding  
CP20 has been introduced for clinical use due to its high affinity toward Fe3+ under physiolog-
ical conditions. However, its chelation selectivity is incomplete because CP20 is also prone to 
bind to different polyvalent metal ions such as Al3+, Ga3+, Cu2+, Zn2+, and Co2+ [3,9,12,31]. This 
behavior might be significant when using the drug in metal poisoning, such as in the case of 
Al3+, or to help in drug design and development [11]. Moreover, CP20 is a small molecule and 
is capable of penetrating cell membranes in addition to large biomacromolecules. This feature 
is attractive for studying CP20’s binding behavior toward different targeted biomolecules.  
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1.1.3.1. Deferiprone-metal ions binding 
CP20 is mainly an iron chelator, and investigation of its binding affinity to metal ions has been 
extensively studied. Dobbin and Hider [3] described the advantages of HPs as alternative for 
hydroxamates and investigated CP20 selectivity for Fe3+ and other essential metals including 
Cu2+, Zn2+, Mg2+, and Ca2+. Moreover, CP20 has been compared to other chelators such as 
ethylenediaminetetraacetic acid (EDTA), DFO, and catechol. CP20 exhibited greater selectiv-
ity toward Fe3+ over other essential metals, and the chelation effect has been estimated ac-
cording to overall binding constant (Logβ) in which Logβ for Fe3+ = 37 >>Cu2+ = 17 >Zn2+ = 
12.5 >>Mg2+ = 7 >>Ca2+ = 4.5. Similarly, Clarke and Martell [9] investigated stabilities of CP20 
chelate containing divalent and trivalent metal ions in solution. There are four trivalent metal 
ions, including Fe3+, Al3+, Ga3+, and In3+, and four divalent metal ions including Cu2+, Zn2+, 
Co2+, and Ni2+ that have been selected for a CP20 binding study. The binding parameters have 
been estimated as overall binding constant (Logβ) and a 1:3 stability constant as the associa-
tion constant (LogKa). CP20 exhibited potent chelation effects toward all trivalent metal ions to 
the same degree as toward Fe3+ and opened the possibility for using CP20 in treatment of 
metal poisoning. Divalent metal ions displayed various binding affinities toward CP20 but to a 
lesser extent toward than trivalent metal ions. As shown in Fig. 6, Al3+ (among trivalent metal 
ions) and Cu2+ and Zn2+ (among other divalent metal ions) are more likely to be chelated by 
CP20 in addition to Fe3+ as a therapeutic target. Thereafter, CP20 has been examined as a 
chelator for Al3+ as described in numerous reports [32–36]. Evaluation of Al3+ levels in different 
organs are difficult to determine due to high variability in the results and the study design; 
however, CP20 is effective in increasing Al3+urinary excretion. 
Moreover, the binding affinity of CP20 toward divalent metal ions has been investigated, and 
CP20 has a significant effect on Zn2+ cellular levels to the point at which Zn2+ deficiency has 
been reported in patients during CP20 treatment [37–39]. The affinity of CP20 towards divalent 
metal ions indicates that CP20 tends to bind to Cu2+ more than Zn2+, but clinical signs, including 
dry/itchy skin, which is indicative of Zn2+ deficiency, are frequently observed [40,41]. Moreover, 
CP20 was reported to induced thymic atrophy. This effect has been attributed to the direct 
chelation effect of CP20 on intracellular Zn2+, which is not observed in treatment with DFO, and 
suggests that CP20 is likely to cause Zn2+ depletion from the cellular stores [37]. Meanwhile, 
CP20 shows a significantly higher affinity for Cu2+ over other divalent metal ions [3,10,12]; 
however, Cu2+ deficiency has been reported to a lesser extent than Zn2+ deficiency [42]. Zn2+ 
deficiency is more observable and more frequently reported. This difference can be attributed 
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to the large variations in the total body amounts between Zn2+ and Cu2+ in which Zn2+ concen-
trations are about 2 gm, which is twenty-five magnitudes higher than Cu2+ (80 mg in the human 
body) [43]; therefore, Zn2+ rather than Cu2+ monitoring is more clinically relevant. 
 
Fig.6. Titration profile of CP20 with different trivalent and divalent metal ions [9]. 
The binding affinity of CP20 to other trace essential metal ions, such as Co2+ and Mn2+, have 
been reported [9,44]. Although the stability constants of these two metals in solution are ap-
proximately similar to Zn2+, the levels of theses essential metal ions were not affected by CP20 
as shown in several animal studies [36,45]. On the other hand, Fatemi et al. described the use 
of iron chelators, including CP20, DFO, and DFX, either as monotherapy or in combination for 
several toxic heavy metals, including Bi, Hg, Cd, Cr (V and VI) and Pb [46–51]. These studies 
revealed the possibility of using iron chelators in removing toxic heavy metals from the body. 
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1.1.3.2. Deferiprone-protein binding 
 In fact, most of the drug interaction studies are carried out with proteins involved in all physi-
ological and pathological processes. In order to understand these processes at the molecular 
level, studying drug interactions with the targeted proteins can help understand these pro-
cesses and provide valuable information. CP20, as a metal chelator, is likely to bind with metals 
that are involved in biomolecule formation. Several proteins are classified as metalloproteins, 
and CP20 might be able to penetrate these large biomolecules and induce either desirable or 
undesirable effects. For instance, CP20 has been reported to interact with Tf, which is the 
major metal-transporting protein in the blood. This interaction can alter the metabolic pathways 
of several metal ions, especially those metal ions that possess levels that compete with Fe3+ 
for metal-binding sites [14,52]. Moreover, CP20 is known to be able to remove Fe3+ from Tf 
binding sites as illustrated in Fig. 7 [53].  
Fig. 7. Fe3+ removal mechanism via CP20 from Tf protein [14]. 
Likewise, human lacoferrin (Lf) is similar to the serum iron binding protein Tf, but is found 
mainly in milk and other external secretions such as saliva, tears, semen, and mucosal secre-
tions. Lf is described as a multifunctional protein due to its binding capabilities with various 
metal ions, small molecules, and biomolecules. Biological functions that are attributed to Lf 
  
11 
 
include antimicrobial, anti-inflammation, iron homeostasis, cell differentiation, and cancer pro-
tection [54,55]. In spite of the fact that the versatility of Lf functions are attributed to direct 
binding with Fe3+ ions, which are crucial to various bioactivities, Lf has been described as bind-
ing directly with other molecules, such as glycosaminoglycans, lipopolysaccharides, and spe-
cific receptors on epithelial and immune system cells. Furthermore, Lf was suggested to bind 
to and interfere with target cell protein kinase and nuclear factor-kB which related signaling 
pathways [56]. These salient functions may cast some light on Lf as a targeted protein. Ac-
cording to FDA and EMA reports [5,6], CP20 has not been known to be secreted in breast milk; 
however, drug secretion as a protein-bound fraction is possible. Lf is most likely a metallopro-
tein found in breast milk, and studying the binding of CP20 with Lf would be valuable for as-
sessing binding parameters and potential of drug secretion in breast milk as a fraction bound 
to Lf. Moreover, the chelation synergism for brain iron has been obtained via exploitation of the 
binding affinity between DFX and Lf as a conjugate, which exhibited more efficacy for iron 
removal from the brain. This process might be useful in neurodegenerative diseases [57]. 
Furthermore, the interaction of CP20 with hemoglobin (Hb) has been investigated, and it was 
found that an interaction occurs via a hydrogen bond and leads to changes in Hb’s confor-
mation [58]. These observations open the door for more investigations in order to evaluate the 
effects of this binding on protein structure and functions. Moosavi-Movahedi et al. [59] investi-
gated the effect of CP20 and DFX on the structure and function of β-Thalassemic Hb using 
multi-spectroscopic techniques. The effects of CP20 are less than those of DFX with respect 
to inducing conformational changes in Hb, which cause a reduction in Hb stability in β-thalas-
semic patients. Another study was implemented by the same research group in order to inves-
tigate the effects of CP20 on inhibition of Hb structural changes during the fructation process. 
CP20 was shown to be capable of preventing the formation of advanced glycation end products 
that are involved in protein aggregation and lead to loss of heme unit; therefore, Hb assembly 
can be affected, especially in diabetic patients [60].  
Therefore, drug interactions with plasma proteins present the main aspect of this study due to 
these interactions’ direct effects on CP20 pharmacokinetics and pharmacodynamics. There 
are several plasma proteins, such as human serum albumin (HAS), α1-acid glycoprotein 
(AGP), lipoproteins, and globulins that are involved in binding to drug molecule; however, the 
major binding partners to the drugs in plasma are HSA and AGP [61,62]. Principally, HSA is 
likely to bind with acidic drugs while AGP tends to bind with basic drugs. Both have the same 
affinity for neutral drug molecules, but this is an oversimplification of the actual situation in 
which, in comparison to AGP, HAS is more likely to be a universal drug binding agent due to 
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high concentrations in plasma and possession of more binding sites [63]. In this regard, there 
is one report in which the interaction between CP20 and HSA is described [64]. CP20 binding 
parameters have been estimated using multi-spectroscopic techniques, including fluorescence 
spectroscopy, circular dichroism, and absorption spectroscopy in combination with molecular 
docking studies (Fig. 8).  
 
Fig. 8. Docking simulation for CP20-HSA interaction [64]. 
1.1.4. Deferiprone analytical aspects 
Over the past three decades, CP20 has been investigated using different analytical techniques. 
Goddard and Knotoghiorghes [65] developed the first high-performance liquid chromatography 
(HPLC) method in order to measure CP20 and other hydroxypyridinone derivatives in serum 
and urine and achieve good separation of CP20 from other hydroxypyridinones in serum and 
urine samples. Moreover, challenges in CP20 chromatography at physiological pH, such as 
peak tailing, have been reported and solved by decreasing the pH to 2 and using ion pair 
reagents. Klein et al. [66] extracted CP20 from human plasma sample and determined CP20 
using the HPLC technique with a carbon-based stationary phase instead of a silica column. 
However, in this method 2 mM EDTA was added to the acidic mobile phase (pH ~ 3) in order 
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to achieve good separation for CP20. Similarly, Epemolu et al. [67] tried several chromato-
graphic approaches for separation of seven hydroxypyridinones, including CP20, by using thin-
layer chromatography (TLC) and HPLC and found poor chromatographic behaviors on bonded 
silica stationary phases. Non-silica-based columns with high carbon loaded exhibited good 
separation for hydroxypyridinone iron chelators. El-Jammal and Templeton [68] determined 
CP20 and related HP compounds in plasma via addition of Fe3+ ions to the acidic mobile phase, 
which contains 0.04% trifluoroacetic acid and 99.96% H2O and separates as a 1:1 chelated 
complex.  
Dresow et al. [69] measured CP20 and its iron complex in serum and urine matrices. The iron 
complex was measured at 450 nm and CP20 at 280 nm; however, no direct separation was 
achieved between CP20 and the iron complex. In this approach, 10 mM octansulfonic acid as 
an ion pair reagent has been used at pH 2.5 in the gradient elution mode. The method has 
been applied to determine the complex in serum and urine samples and then the iron content 
in urine was estimated by HPLC and atomic absorption spectroscopy. Recently, Song et al. 
[70] developed a liquid chromatography with tandem mass spectroscopy (LC–MS/MS) method 
with a pharmacokinetic application for determination of CP20 in human plasma. The resulting 
method was utilized to recover CP20 in serum samples at a very low concentration range (0.1–
20 μg/mL), and in this approach EDTA was used in the mobile phase in order to improve the 
separation of CP20 in biological samples. The MS/MS detector in product ion mode has been 
utilized to identify the product ion mass spectra of CP20. 
On the other hand, there is only one reported capillary electrophoresis (CE) method for deter-
mination of CP20 and DFO in human plasma. Lin et al. [71] developed a new CE method for 
CP20 and DFO monitoring in patients’ plasma. The determination of targeted iron chelators 
was carried out using a CE stacking strategy and 150 mM sodium dodecyl sulfate (SDS) in 
micellar form in 100 mM phosphate buffer at pH 3, while BGE was optimized at pH 6.6 using 
100 mM phosphate buffer. This method was sensitive enough to monitor DFO and CP20 in 
real thalassemic patients’ plasma samples.  
 In fact, the aforementioned chromatographic and electrophoretic methods are good ap-
proaches for overcoming the challenges of CP20 separation although separation of CP20 from 
its iron complex was still not achieved using these methods. Some methods used ion pair 
reagents and some others used competing chelators. CE method used SDS and triethanola-
mine as buffer additive. Hence, these approaches are intended for analytical use that is aimed 
at determining CP20 in biological samples. However, the system’s complexity is the main draw-
back, and no reported method that is capable of separating CP20 from iron complex in a single 
run has been reported.   
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1.1.5. Aim of the work.  
There is a still need to further investigate CP20 and its behavior as a chelator. CP20 capability 
to chelate essential metal ions, inhibit catalytic enzyme activities, or even directly bind to tar-
geted biomolecules is interesting. Further steps in this direction might be enlightening with 
respect to new biological activities, which could aid in the development of new pharmacological 
uses. In this context, this work aims to develop new analytical approaches for investigating 
CP20 binding behavior to different targets. The first goal is to develop new LC/MS and CE/FA 
methods for determination of CP20 and separation of the free-form drug from the iron complex 
in order to investigate its binding affinity. It is well known that the CP20 separation is still a chal-
lenge, and no reported method has been able to achieve separation in one single run to date. 
The second goal is exploitation of MS as a powerful tool for characterizing binding stoichiom-
etry. Furthermore, the binding affinity of CP20 towards essential metal ions in temperature 
gradient has not yet been studied. Therefore, investigation of CP20 binding affinity to essential 
divalent metal ions in addition to iron using MST is the third goal. On the other hand, the study 
of CP20 interaction with proteins is still poor and there is only one publication for characterizing 
CP20 interaction with HSA using spectroscopic techniques [64]. Therefore, the investigation 
of CP20 with HSA using MST and ACE techniques is the fourth goal of this work. Subsequently, 
exploiting MST and ACE to investigate the interaction of CP20 with human lactoferrin as a 
targeted protein in human breast milk is the fifth goal to predict the possibility of drug secretion 
as a fraction bound to protein.    
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2. Analytical techniques 
2.1. Separative analytical techniques 
2.1.1. Liquid Chromatography Mass Spectrometry  
LC/MS is a hyphenated technique that exploits the power of the two technologies in one com-
bined instrument. The separation power of HPLC was aided by the detection power of MS to 
produce LC/MS, which nowadays is the technique of choice for a broad range of analytical 
applications [72].  
An HPLC instrument (Fig. 9) consists of several main parts connected in sequence starting 
from mobile phase reservoirs that are connected to a pumping system for delivering the liquid 
mobile phase and injecting analyte sample into the stationary phase in which chromatographic 
separation take place. In between the pump and stationary phase, the sample injector or au-
tosampler is the point at which the analyte sample can be injected and delivered for separation 
inside the stationary phase. Thereafter, the separated samples are eluted and pass through 
the detector cell, and signal is then detected and recorded.  
 
Fig. 9. Scheme of HPLC instrument including the main parts as (1) mobile phase reser-
voir, (2) pump, (3) sample injector, (4) stationary phase, (5) detector, (6) waste 
reservoir, and (7) Data records. 
 
HPLC is a well-known separative technique consisting of different separation mechanisms, 
such as partitioning, size exclusion, and ion exchange. Partitioning mechanisms have been 
extensively utilized to characterize the analyte molecules that are partitioned between two 
phases that differ in polarity; one is the stationary phase, and the other one is the liquid phase. 
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Nevertheless, normal phase liquid chromatography (NPLC) is ideal for analyte partitioning be-
tween the polar stationary and non-polar liquid mobile phases, while the opposite mode is 
known as reversed-phase liquid chromatography (RPLC) in which the phases are reversed. 
The samples that are partitioned between the two phases are exposed to numerous interac-
tions, such as dipole-dipole and electrostatic interactions, hydrogen bonding, and diffusion. 
These interactions take place according to the nature of the analyte’s physicochemical prop-
erties and types of stationary and mobile phases in the LC system [73]. Furthermore, for LC 
analysis of large molecules, such as proteins, the use of the size exclusion mechanism is ideal 
due to its capability to separate the analytes depending on their molecular sizes. Moreover, 
ion chromatography is related to charged molecules and metal ions and has wide applications 
in environmental analysis [74] and to a lesser extent, in protein purification [75].  
The versatility of HPLC is based on several separation phases. However, the RPLC mode is 
used predominantly in pharmaceutical development and enables researchers to separate a 
wide range of pharmaceutical compounds depending on their polarities. Therefore, RPLC is 
the most important mode described in this study. 
RPLC separation is achieved by introducing the sample to the polar mobile phase consisting 
of aqueous solution and organic solvents. The ratio of the mobile phase components can be 
either in a fixed ratio, which known as isocratic elution, or changeable ratio, which known as 
gradient elution. Mobile phase solvents, including methanol, acetonitrile, isopropanol, and tet-
rahydrofuran, are frequently used. Also, different buffer salts and buffer additives can be added 
in order to achieve the desired separation. 
The stationary phase in RPLC is non-polar in which the silica support has been chemically 
modified with derivatized n-alkyl silane as the hydrophobic ligand. The most common ligands 
for routine analysis of pharmaceutical and biopharmaceuticals are n-octadecyl (C18), n-octyl 
(C8), and n-butyl (C4). Thereafter, different types of ligands, such as phenylpropyl, cyanopro-
pyl, and/or aminopropyl silane, could be added to expand the selectivity of the silica support 
[76]. 
 Furthermore, several experimental parameters should be considered in order to obtain ideal 
chromatograms, including mobile phase compositions, stationary phase type, flow rate, tem-
perature, and pH, whereas system optimization is the first step in the development of an HPLC 
method in order to control the effects of these parameters on the separation. 
Theoretically, there are a number of parameters for characterizing the chromatographic per-
formance according to the obtained chromatogram as shown in Fig. 10. 
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Fig. 10. Illustration for HPLC chromatogram with theoretical parameters.  
 
The retention factor (K) is calculated according to the equation: 
 
𝐾 =
𝑡𝑅 − 𝑡𝑜
𝑡𝑜
 
in which 𝑡𝑜 is the dead time, and 𝑡𝑅  is retention time. 
The retention factor is a unitless value, is considered an independent factor, and is character-
istic for analyte under the same conditions in different laboratories [73]. 
Selectivity (α) is defined as the relative retention between two analytes and is calculated based 
on the K value of each compounds: 
 
∝ =  
𝑘2
𝑘1
 
in which α is dependent on the chromatographic phase and temperature.  
Furthermore, the separation efficiency can be calculated with respect to number of theoretical 
plates (N) and resolution (Rs): 
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The number of theoretical plates is calculated according to the equation: 
 
N = 16 (tR/w)2  
 
in which N = number of theoretical plates, tR = retention time, and w = peak width at the base.  
 
Resolution (Rs) is defined as a separation measurement between two adjacent peaks and is 
calculated based on the following equation: 
 
Rs = 2 (tR2 - tR1/w2 + w1) 
 
Both N and Rs parameters correlate with the stationary phase and indicate the efficiency of the 
selected column in order to achieve good separation depending on column length, particle 
size, and flow rate [77].    
MS in conjunction with HPLC as detection technique are valuable for yielding information about 
samples identification. Under a vacuum, MS can be applied to analyze the ionized samples 
according to their mass to charge ratio (m/z). Therefore, the MS instrument can be used for 
three consecutive processes: (1) sample ionization; (2) mass analysis; and (3) mass detection. 
The ionization process is implemented via several ion sources, which are classified as hard 
ion sources or soft ion sources in which soft ion sources are widely used due to their compati-
bility with biological samples where, low energy conveyed to conserve the intact biomolecules 
without occurring further fragmentation [78,79]. The soft ionization including atmospheric pres-
sure ionization (API), which consists of several modes of ion sources such as electrospray 
ionization (ESI), atmospheric pressure chemical ionization (APCI), and atmospheric pressure 
photoionization (APPI) are favored for adaption with LC techniques in addition to matrix-as-
sisted laser desorption ionization (MALDI). The second step is the mass analysis process in 
which mass analyzers are classified according to low- and high-resolution mass analyzers. 
Low resolution MS analyzers include quadrupole (QMS) and ion trap (QiT) while high-resolu-
tion mass analyzers include time of flight (TOF), orbitrap, and Fourier transform ion cyclotron 
resonance (FTICR) [78,80,81]. However, a single quadrupole mass spectrometer equipped 
with ESI as ion source (ESI-MS) will be described here (Fig. 11). 
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Fig. 11. ESI-MS instrument. 
 
The ESI-MS instrument as shown in Fig. 11 was designed based on three consecutive pro-
cesses: (1) sample ionization that takes place in the ESI ion source, whereas the liquid sample 
that comes from the HPLC are pumped into an orthogonal metal capillary called a nebulizer. 
Under atmospheric pressure, the eluent under the electrical field in the nebulizer is sprayed 
into a spray chamber to form a droplet. The formed droplets are evaporated via application of 
dry heated nitrogen gas; thereby, an electrostatic field occurs between the nebulizer and ca-
pillary in order to control the movements of ionized molecules into the MS vacuum; (2) mass 
analysis in which the quadrupole mass analyzer consists of four parallel metal rods, and the 
ions filter selectively through the oscillating electrical field of radio frequency between the rods 
according to mass to charge ratio. Therefore, only certain ions can pass through quadrupole 
track per time unit; and (3) mass detection, after the selected ions pass through the mass 
analyzer, they can be detected, and signals can be recorded [78,80].   
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2.1.2. Capillary electrophoresis 
Capillary electrophoresis (CE) is an alternative separative technique to LC, and it gained pop-
ularity in a wide range of applications. CE and LC are separative techniques, and almost the 
same parameters are chosen for the analytical method’s efficiency and sensitivity; however, 
CE is different than LC with respect to the separation mechanism. CE separates the charged 
analytes depending on their size and charge in free solution. The analytes exhibit different 
velocities within the electrical field [82]. 
 
Fig. 12. Illustration for CE instrument. 
 
The instrument (Fig. 12) consists of a fused-silica capillary with an internal diameter range of 
25 to 100 μm and an optical detection window. Each end of the capillary was immersed in the 
buffer reservoir, which was connected to the power supply via two electrodes. The detector is 
aligned with the detection window in the capillary, and optical detectors, such as ultraviolet–
visible (UV–vis) or fluorescence detectors, are attached to the instrument. 
Furthermore, the sample was injected hydrodynamically or electrokinetically into either one of 
the capillary ends; therefore, the capillary is divided into total and effective lengths according 
to the sampling location, whereas the effective capillary length is the length of the capillary that 
is used for separation up to the point of the detector. The total capillary length includes effective 
length plus capillary length after the detection window. Nevertheless, the detection window is 
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designed with an enclosed electrode (typically the cathode); therefore, the injection could be a 
long- or short-end injection according to the effective capillary length that is chosen [83]. 
In principle, the separation in the CE system is dependent on the movements of charged mol-
ecules through the narrow bore capillary (usually made of bare fused-silica glass); thereby, 
these movements occur under the effects of electrophoresis or electroosmosis. Initially, elec-
trophoretic mobility was created due to generation of an electrical field in which the applied 
voltage (usually 10–30 kV) tends to initiate ion migration toward the opposite electrode (cath-
ode pull the cations while anode pull the anions). However, electroosmotic mobility is greater 
than electrophoretic mobility, resulting a generation of an additional potential (zeta potential) 
on the capillary surface. This process leads to flow movements in one direction for the overall 
movement of running buffer inside the capillary. This phenomenon is known as electroosmotic 
flow (EOF). Herein, the separation is depending on vector sum of two movements which allows 
for differentiation between the analytes depending on their charge to mass ratio. EOF, as 
shown in (Fig. 13), exists in each CE system in which negative charges are generated on the 
surface of the silica capillary due to ionization of silanol function group at pH >2.5 (Fig 13 A). 
The hydrolyzed cations that exist in aqueous buffer are attracted to the negative charges on 
the capillary wall and thus, create a double layer (Fig. 13 B). Subsequently, by applying an 
electrical voltage, they migrate toward cathode with an action that is similar to the pumping 
effect in LC (Fig. 13 C) [83,84].  
 
Fig. 13. EOF generation in CE system. 
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Migration in CE occurs under an electrical field; however, the solution’s chemistry is critical for 
generating charged analytes and exhibiting efficient separation in a CE system in addition to 
EOF generation. Therefore, an EOF velocity is governed according to the equation [83,85,86]: 
 
𝑉𝑒𝑜𝑓 = − (
𝜀𝜁
4𝜋𝜂
) 𝐸    (1) 
 
in which ε is the dielectric constant of electrolytes, ζ is zeta potential (volts) for measuring the 
charges on the wall of capillary, ƞ is the viscosity, and E is the applied potential. From the 
equation, EOF velocity is shown to be significantly affected by pH. In an acidic environment (at 
pH ≤3) EOF effect is minimal due to the silanol group’s ionization state, whereas the effect of 
EOF increasing at neutral pH in which case fused silica behaves as weak acid with a pKa 6.25 
as shown in Fig. 14 [85].  
 
 
Fig. 14. EOF and silica ionization degree along pH scale [85]. 
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An increase in buffer concentration leads to a decrease in EOF velocity. Charge density as 
represented by zeta potential (ζ) is directly proportional to EOF velocity. Therefore, the flow in 
CE capillary is a plug flow in contrast to the parabolic flow in LC as shown in Fig. 15.   
 
 
Fig. 15. EOF flow versus hydrodynamic flow. 
 
All of these factors have been taken into account for the use of an uncoated fused silica capil-
lary, which is the most extensively used capillary type in CE methods. However, it could be 
derivatized with different molecules, such as polyvinyl alcohol, polyacrylamide, or polyethylene 
glycol. This type of coating might be used for specific applications. For instance, adsorptive 
substances, such as highly positively charged proteins, are impossible to separate under nor-
mal CE conditions. Therefore, the EOF can be altered to suit the application [86]. 
Furthermore, are other factors such as temperature, applied voltage, capillary length and di-
ameter, and injection volume should be taken in account whenever undertaking CE analyses. 
However, temperature control is significant for obtaining reproducibility in CE separation, but 
the temperature is generated from different sources and thereby temperature fluctuation can-
not be totally avoided but should be minimized. For instance, the electrical current will generate 
heat when it passes through the running buffer inside the capillary; this heat is called Joule 
heating (JH). Actually, JH can be estimated according to the formula [87]: 
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𝑃 =
𝜋𝑘𝑑𝑖
2𝐸2𝐿
4
        (2) 
 
in which P is Joule heat that is produced, k is conductivity, di is the capillary’s internal diameter, 
E is the electrical field strength, and L is the capillary length. Obviously, the generated heat 
correlates with several factors, such as capillary dimension, electrolyte conductivity, and elec-
trical current. The electrical current increases directly with the increase in capillary diameter, 
leading to an increase the resulting JH. Practically, JH might alter EOF via alterations in running 
buffer viscosity as described in equation (1).  
Additionally, applied voltage plays an important role in the analyte’s separation via an increase 
in EOF, leading to an increase in sample migration with a concomitant shortening in analysis 
time. However, increasing the applied voltage might increase the electrical current, which pro-
duces JH as an adverse effect resulting from an increase of applied voltage [84,85].  
In CE, the capillary is the heart of system similar to the column in HPLC. The effect of capillary 
dimensions and properties are described and explained as critical factors that affect both EOF 
and HJ generation. However, capillary regeneration also is critical in order to exhibit a repro-
ducible result. Capillary regeneration of bare-fused silica is usually achieved using 0.1–1 M 
sodium hydroxide (NaOH) to hydrolyze the silanol group, which is important for generating 
EOF. Therefore, washing procedures should be optimized during the CE development method 
according to the type of analytes and electrolytes in the CE system [85]. 
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2.1.2.1. Affinity capillary electrophoresis 
Exploiting CE for binding affinity studies is considered one of the major CE applications. Affinity 
capillary electrophoresis (ACE) is the CE based methods that allowed the binding investigation 
in free solutions without the need for immobilizing one partner on the supporting matrix. More-
over, ACE as performing at near physiological conditions, low sample consumption, low cost, 
short analysis time, and possible adaptation to various detectors. In addition, CE presents a 
great advantage for miniaturization of instrumental analysis [62,88–91]. ACE can be imple-
mented with several CE-based methods according to several kinetic equilibrium modes: 
A. The dynamic equilibrium mode in which this mode is distinguished from other modes 
by with rapid binding kinetics. In this mode, the equilibrium relaxation time is shorter 
than migration time. Actually, most of the CE modes, including mobility shift ACE 
(mACE), Hummel-Dreyer (HD), vacancy peak (VP), and CE frontal analysis (CE/FA) 
belong to this mode of equilibrium kinetics. 
B. The pre-equilibrated mode is distinguished by slow kinetics in which the relaxation 
time of equilibrium is longer than the migration time. In this mode, equilibration should 
occur before subjecting the sample to CE analysis. CE modes, which are suitable to 
be used for this mode of kinetics are CZE and CE/FA in which the dissociation in CE 
system is negligible due to high binding affinity. 
C. The intermediate mode is the kinetic mode which is used to describe the dissociation 
of binding equilibrium in which the relaxation time is equal to the separation time. In 
this mode, the co-eluted peak has been observed on electropherograms due to disso-
ciation of the complex. This mode of kinetics might be observed in pre-equilibrated 
CZE [92].  
Therefore, CE exhibits several responses for quantifying the binding event depending on the 
equilibrium type; thereby, there are different CE-based approaches that might be implemented 
as described in Table 1 [62,89,93–95].  
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Table 1. CE modes for binding affinity studies. 
 Pre-equilibrated 
mode 
Dynamic equilibrium mode 
 CE/FA CZE mACE HD VP 
Setup 
   
Binding pa-
rameters 
-binding constant 
- stoichiometry  
-Binding 
constant 
-binding con-
stant 
-Stoichiometry 
- binding constant 
- stoichiometry 
Binding kinet-
ics 
Fast and 
slow  
Slow  Fast Fast Fast 
Electropho-
retic re-
sponse 
Peak plat-
eau height 
or area 
Peak 
area or 
height 
migration 
time shift 
Peak area or 
height 
Peak area or height 
CE/FA CE 
profile 
 
CZE CE pro-
file 
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mACE CE 
profile 
 
HD CE profile 
 
VP EC profile 
 
CE/FA A- Advantages 
1. It can be used for Both slow and fast equilibria  
2. Multi kinetic equilibrai can be estimated 
3. Binding stoichiometry can be estimated 
4. The drug bound fraction have been easily obtained 
B- Diadvantages 
1. Not possible for non chromophoric partner 
2. Sample might be consumed more than other ACE modes  
mACE A- Advantages 
1. Suitable for non-chromphoric interacting partner 
2. enantiomeric separation is easy to perform 
3. using with sample mixture 
B- Disadvantages 
1. Not used in multi kinetic equilibria. 
2. Binding stoichiometry cannot be estimated 
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 2.1.3. Binding fundamentals in the separative techniques 
Binding parameters, such as both binding constant and stoichiometry, are the most important 
parameters that have been used in characterizing the binding events. Although many forms of 
symbols were assigned to the binding constant, all refer to the association/dissociation rate at 
equilibrium: 
[𝐷] + [𝑇]    
𝐾𝑎
⇌
𝐾𝑑
   [𝐷𝑇]          (1) 
in which [D], [T], and [DT] are the molar concentrations of free drug, free targeted molecule, 
and the complex, respectively, and Ka and Kd are the association and dissociation constants, 
respectively. At equilibrium, the association rate is equal to dissociation rate and the binding 
constant can be defined using the equation: 
𝐾𝑎 =
1
𝐾𝑑
⁄ =  
[𝐷𝑇]
[𝐷][𝑇]
             (2) 
 
Hence, the total drug and the target concentrations are known, but the complex concentration 
is unknown and can be calculated as the bound fraction, r, which denotes the number of total 
drugs bound per target at equilibrium in which K=Ka: 
𝑟 =  
[𝐷𝑇]
[𝐷][𝑇]
=  
𝐾[𝐷]
1+𝐾[𝐷]
            (3) 
 
Based on Equation (3), r can be replaced by an experimental response base on the equation: 
 
∆𝑅
∆𝑅𝑚𝑎𝑥
=
𝑅−𝑅𝑓
𝑅𝑐 −𝑅𝑓
=
𝐾[𝐷]
1+𝐾[𝐷]
         (4) 
 
in which R is the system response, Rf and Rc are the responses of free target and complex, 
respectively. The experimental response is expressed according to the selected analytical ap-
proach, such as mobility shift in ACE and retention factor in chromatography. In these ap-
proaches, the equilibrium kinetics are rapid, and the complex is difficult to stabilize in the sys-
tem. In addition, the effects of viscosity, ionic strength, and sample adsorption should be taken 
into account. The binding constant according to Eq. (4) can be estimated using a nonlinear 
least-squares regression, and the binding stoichiometry was assumed to be a 1:1 binding ratio. 
Furthermore, several algebraic rearrangements have been addressed for linearizing the rela-
tionship [94,96]: 
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∆𝑅
[𝐷]
=  −𝐾∆𝑅 + 𝐾∆𝑅𝑚𝑎𝑥                (5) 
[𝐷]
∆𝑅
=  
1
∆𝑅𝑚𝑎𝑥
+
[𝐷]
∆𝑅𝑚𝑎𝑥
                      (6) 
1
∆𝑅
=
1
∆𝑅𝑚𝑎𝑥𝐾[𝐷]
+
1
∆𝑅𝑚𝑎𝑥
                (7) 
  
Equations 5–7 represent different linear plots for Eq. (4). These algebraic rearrangements 
have been named x-, y-, and double reciprocal, respectively. 
For multiple equilibria systems that occur in biological system, Eq. (3) has been modified to 
[94,97,98]: 
𝑟 =
[𝐷]
[𝑇𝑡𝑜𝑡𝑎𝑙]
=
𝑛.𝐾[𝐷]
1+𝐾[𝐷]
                      (8) 
 
in which n is the total number of binding sites per target.  
In this system, different binding affinities can be assumed based on the following equation: 
       
𝑟 = ∑
𝑛𝑖 . 𝑘𝑎 . [𝐷]𝑓𝑟𝑒𝑒
1 + 𝑘𝑎  . [𝐷]𝑓𝑟𝑒𝑒
            (9)
𝑚
𝑖=1
 
 
in which m is the independent binding types per target. In this system, binding parameters can 
be estimated using a nonlinear least-squares regression, and the total number of binding sites 
can be estimated to yield information about binding stoichiometry.  
According to Eq. (9), data can be fitted with fast and slow kinetic equilibrium constants depend-
ing on several separative analytical approaches, such as direct LC separation, CZE, and 
CE/FA. This formula can be used to estimate the binding parameters according to separation 
of free drug from the complex. Herein, the experimental response can be addressed in order 
to obtain the concentration of free drug based on an external calibration curve. 
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2.2. Non-separative techniques 
2.2.1. Microscale thermophoresis 
Microscale thermophoresis (MST) is a relatively new biophysical technique derived the basic 
principle from physical phenomenon known as thermophoresis (also defined in other syno-
nyms as thermomigration, Soret effect and thermodiffusion) which describing the movement 
of the molecules through temperature gradients [99]. The suffix -phoresis indicating the migra-
tion of analytes and this migration might be under electrical field as occurs in CE or under 
temperature gradient as occurs in MST (Fig. 16).  
  
 
Fig. 16. MST illustration for thermomigration under temperature gradient. 
 
The movement of molecules along temperature gradients is influenced by changes have been 
induced through molecular binding leading to change of molecular properties as charge, size 
and hydration shell [99–101].  Thermophoresis can occur in all phases of matter and described 
at the first time by Carl Ludwig in 1856 [102]. Since then thermophoresis has been exploited 
in different areas of research such as inorganic polymerization and aerosol mixtures [103,104]. 
Braun and Libchaber described the first approach of thermophoresis for biomolecule with trap-
ping of DNA and characterizing of thermophoretic depletion. DNA was depleted from heated 
zone and thermal diffusion constant (DT) has been quantified for the first time [105,106]. More-
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over, Piazza and coworkers reported the effect of thermophoresis in protein solution and pro-
vided information’s about particle-solvent interactions through studying the effect of protein 
charge and salt additives on lysozyme Soret coefficient [107,108]. Actually, all of the previous 
reports have been dealt with theoretical framework of Soret effect for biomolecules in solution 
however, Duhr and Braun studied all parameters that govern thermodiffusion including particle 
surfaces, size, effective charge, temperature and salt concentration to measure Soret coeffi-
cient (ST) for DNA and polystyrene beads whereas, postulated the theoretical formula of ther-
mophoresis in solution have been postulated (section 2.2.1.2). Moreover, they stated that “ther-
modiffusion can be miniaturized to micrometer scale with all optical fluorescence technique and permit 
microscopic temperature differences to manipulate molecules based on their surface properties” [109]. 
Thermophoresis in microscale units was described by Dieter Braun and coworkers via studying 
thermophoresis of single strand of DNA in native bulk solution. Where temperature gradients 
were induced locally using infrared laser focused on rectangular capillary with a 50 μm x 50 
μm cross section [110]. Thereafter, the same research group was introduced MST as analytical 
tool in characterizing the interactions of biomolecules. The experiment was carried out using 
lab-made MST instrument where temperature gradients were created through using infrared 
laser diode 1480 nm and microfluidic chambers using fused silica capillary with inner diameter 
100 μm. The technique was succeeded in determination of Kd in nanomolar concentration for 
two different approaches of protein interactions [111]. Nowadays, MST is exploited extensively 
in characterizing the interaction of several biomolecules such as protein-protein interactions 
[112–114], protein-nucleic acids interactions [115,116]], protein-small molecules interactions 
[117–119], protein-metal ions interactions [120,121] and many other molecular interactions that 
possessed significant applications in life sciences.  
Indeed, MST has been introduced to bioanalysis realm with several features to fill the gap 
between the competing biophysical techniques such as surface plasmon resonance (SPR), 
isothermal titration calorimetry (ITC), and several spectroscopic techniques [122]. For instance, 
MST allow to measuring the binding events in free solution by avoiding immobilization of one 
binding partner that might alter the binding event. Whereas, the surface immobilization process 
is necessary step in SPR for creation of sensitive sensor to measure the binding kinetics which 
is the main advantageous of SPR technique however, there are many drawbacks of this artifact 
such as binding overestimation and concentration depletion [122–124]. Furthermore, MST ex-
hibit high flexibility to use buffers without restrictions unlike ITC which is restricted to buffers 
with low enthalpy ionization to minimize the overlapping of heated signals although ITC gives 
affinity, stoichiometry and thermodynamic parameters in free solution and label free system, 
but it suffers from low sensitivity, slow throughput technique, time consumption and high 
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amount of sample need to obtain sufficient heat signals [118,123]]. Besides, spectroscopic 
techniques including fluorescence anisotropy (FA) and fluorescence correlation spectroscopy 
(FCS) are fluorescence-based methods and similar to MST. Whereas, FCS technique depend 
on change on diffusion time of fluorescent molecules through detecting of fluorescence fluctu-
ation upon the diffused fluorescent molecules out the focused volume. While, FA almost has 
the same principle except that measure change in rotational diffusion time thereby, polarized 
time has been used to excite the fluorescent partner. Both techniques have been dedicated 
mainly to single molecule applications more than biomolecular interaction as well as time con-
suming and need to perform more optimization in comparison to other biophysical techniques 
[100,114,125,126]. Table. 2 compare between SPR, ITC and MST as promising biophysical 
techniques that are used in biomolecular interaction.  
   
Table 2. Comparison between ITC, SPR and MST techniques 
 
Biophysical technique 
 
Advantages 
 
Disadvantages 
 
ITC 
• Several physical parameters 
can be obtained from one 
single experiment such as 
binding constant, binding 
stoichiometry and binding 
enthalpy. 
• Immobilization is not re-
quired 
• Labeling is not required 
• Inexpensive technique 
• Large sample consump-
tion 
• kinetic data cannot be ob-
tained 
• Buffer should be with low 
enthalpy 
• Low throughput 
• Low sensitivity 
• Time consuming 
 
 
SPR 
• Binding kinetic in real time is 
possible 
• Label free system 
• Highly Sensitive technique 
• High throughput 
• Low sample consumption 
• Expensive technique 
• Immobilization of one 
binding partner is required 
and time consuming 
• Experiment need to tech-
nical skills to perform 
• Immobilization of one of 
the binding partners re-
quired 
• Instrument maintenance 
 
 
MST 
• Low sample consumption 
• Simple handling technique 
• Immobilization free 
• Lebel free system is possible 
• Enabling to wide range of 
molecules i.e. ions to MDa 
biomolecules. 
• High throughput. 
• Non-specific binding is 
possible due to labeling 
procedures. 
• Binding kinetics cannot be 
obtained 
• Expensive instrument 
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2.2.1.2. MST principle and theory  
Through infrared (IR) laser beam with emission wavelength 1480 nm (Fig. 17 A), the local 
heating of aqueous solution in diameter of ~ 50 µm and temperature difference ∆T ~ 2-6⁰C will 
generate molecular flow (j) which is directly proportional to temperature gradient with propor-
tionality constant DT. In steady state, thermophoretic flow opposed by mass diffusion and both 
effects being balanced which are describe in the following equations [109,111,122,127]: 
𝑗 =  −𝑐𝐷𝑇     grad T      (1) 
𝑗 =  −𝐷       grad c     (2) 
j: molecular flow; c: molecular concentration; DT: Thermal diffusion coefficient; T: temperature; 
D: diffusion coefficient. The Soret coefficient ST is defined by the ratio: 
𝑆𝑇= 
𝐷
𝐷𝑇
              (3) 
ST describes the concentration ratio under steady state conditions and given by: 
𝑆𝑇:
𝐶ℎ𝑜𝑡
𝐶𝑐𝑜𝑙𝑑
 = 𝑒𝑥𝑝(−𝑆𝑇∆𝑇)  (4) 
where Chot is the concentration of molecules at the hot zone and Ccold is the concentration of 
molecules at the cold zone. ST is Soret coefficient, which is affected by the factors described 
in the following equation: 
𝑆𝑇 =  
𝐴
𝑘𝑇
(−∆𝑠ℎ𝑦𝑑(𝑇) +
𝛽𝜎2𝑒𝑓𝑓
4𝜀𝜀0 𝑇
×  𝜆𝐷𝐻 )      (5)      
where A is the surface area of the molecules, σeff is the effective charge, ∆shyd is the hydration 
shell effect, λDH is the Debye–Hückel screening length, ɛ is the dielectric constant, and β is 
temperature derivative of ɛ. Therefore, any small conformational changes of thermophoretic 
parameters such as effective charges, hydration entropy or molecular size provide information 
about binding affinity.  
In principle, thermophoresis has been carried out in free solution inside cylindrical capillaries 
and MST signals that obtained involves of numerous subsequent processes. Initially, MST 
records fluorescence in the focal of IR-laser zone at ambient temperature without laser heating 
which called initial state (Fig. 17 B-I). Then, IR-laser turn on for heating of specific focal zone 
in sample solution and leads to change of fluorescence intensity known as T-jump (Fig. 17 B-
II). After T-jump, thermophoretic movements of the molecules start as well as fluorescence 
intensity will decrease till reach to the steady state depend on molecular depletion to out of 
heated zone according to the typical thermophoresis which described as the movement of the 
molecules from hot to cold zone (Fig. 17 B-III). Thereafter, IR-laser switched off to induce mass 
diffusion of molecules depends on concentration gradient which called back-diffusion state 
(Fig. 17 B-IV). The total time for each MST signal takes ~35 seconds. 
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Fig. 17. A) Schematic setup of MST instrument. B) Subsequence stages of thermophore-
sis. C) Thermophoretic signals for bound/unbound molecules (left), Binding 
curve (right) [127]. 
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Herein, binding quantifications is taking place by analyzing the change in fluorescence intensity 
which estimated as relative fluorescence (normalized fluorescence) according to the following 
equation: 
 𝐹𝑛𝑜𝑟𝑚 =  
𝐹ℎ𝑜𝑡
𝐹𝑐𝑜𝑙𝑑
⁄        (6) 
Whereas, 𝐹𝑛𝑜𝑟𝑚: normalized fluorescence; 𝐹ℎ𝑜𝑡: fluorescence in heated zone; 𝐹𝑐𝑜𝑙𝑑: fluores-
cence at initial state or in cooling state. The differences in 𝐹𝑛𝑜𝑟𝑚 of the bound and unbound 
state (depend on the concentration of titrated partner) allow to estimate fraction bound (𝐹𝐵) as 
shown in (Fig. 17 C) according to the following equation: 
𝐹𝑛𝑜𝑟𝑚 = (1 − 𝐹𝐵)𝐹𝑛𝑜𝑟𝑚(𝑢𝑛𝑏𝑜𝑢𝑛𝑑) + (𝐹𝐵)𝐹𝑛𝑜𝑟𝑚(𝑏𝑜𝑢𝑛𝑑)      (7) 
Thus, 𝐹𝑛𝑜𝑟𝑚 is used to quantify the concentration of fluorescent molecules which is temperature 
dependence and governed by the flowing equation: 
𝐹𝑛𝑜𝑟𝑚 =  
𝐹ℎ𝑜𝑡
𝐹𝑐𝑜𝑙𝑑
⁄ = 1 + (
𝛿𝐹
𝛿𝑇
− 𝑆𝑇) ∆𝑇 =
𝐶ℎ𝑜𝑡
𝐶𝑐𝑜𝑙𝑑
+
𝛿𝐹
𝛿𝑇
∆𝑇      (8) 
2.2.1.3. MST data analysis 
Binding isotherm of MST can be illustrated as shown in (Fig. 17 C right) where x-axis is the 
molar concentration of the sample against the relative fluorescence % on the y-axis. Actually, 
there are two binding models that have been implemented to fit MST data. The first, assuming 
the binding stoichiometry to be 1:1 binding ratio or multiple binding ratios with the same affini-
ties. In this case, the dissociation constant Kd can be estimated as follow [100,111,127]: 
𝐴 + 𝐵 ⇌ 𝐴𝐵      (1) 
A: binding partner A; B: binding partner B; AB: complex 
The equilibrium dissociation constant Kd as:  
𝐾𝑑 =
[𝐴]𝑓𝑟𝑒𝑒−[𝐵]𝑓𝑟𝑒𝑒
[𝐴𝐵]
      (2) 
Whereas, free concentrations of each partner are not known. Total concentrations are used 
according to the following formula: 
[𝐴] = [𝐴]𝑓𝑟𝑒𝑒 + [𝐴𝐵] 𝑎𝑛𝑑 [𝐵] = [𝐵]𝑓𝑟𝑒𝑒 + [𝐴𝐵]    (3) 
[𝐴]𝑓𝑟𝑒𝑒: free concentration of partner A; [𝐵]𝑓𝑟𝑒𝑒: free concentration of partner B; [𝐴𝐵]: bound 
complex concentration.  
Hence, Kd is calculated as follow: 
𝐾𝑑 =
([𝐴]−[𝐴𝐵])([𝐵]−[𝐴𝐵])
[𝐴𝐵]
             (4) 
Then, fraction bound FB is calculated as a total concentration of A and B and correlated with 
Kd parameter as follows: 
𝐹𝐵 =
[A]+[B]+𝐾𝑑−√([𝐴]+[𝐵]+𝐾𝑑)2−4[𝐴𝐵]
2[𝐵]
        (5) 
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Where, FB represents linearity with normalized fluorescence form MST measurements.  
The second model is implemented when the binding events is more complicated in which more 
than one binding sites with different affinities or cooperative systems. In these cases, Hill co-
efficient and EC50 have been estimated according to hill equation: 
 
𝐹𝐵 =
1
1+(𝐸𝐶50 𝐵)𝑛⁄
                     (6) 
Where B represent concentration of titrated partner. EC50 is defined as half maximal concen-
tration of titrated partner which provide information about affinity of two partner depends on 
their concentration and n is Hill coefficient which provide information about system cooperativ-
ity. 
2.2.1.4. Experimental implementation of MST 
Implementation of MST experiment require discussing some important issues such as MST 
instrumentation, samples preparation, and MST optimization.  
2.2.1.4.1.  MST instrumentation 
MST instrument as illustrated in Fig. 17 A consists of visible light passed through an objective 
to induce fluorescence excitation/emission for fluorescent molecules in specific μm- zone of 
the sample inside a glass capillary. Afterwards thermophoresis will be generated through 
switching on the IR laser to pass throughout the same objective and heating specific local zone 
inside the zone of fluorescence excitation light. The two beams of light are perpendicular 
whereas, IR light focus beam is switched on and off each 35 S and is reflected via dichroic 
mirror to couple with visible light. The position of local zone should be fixed in each capillary 
and can be tested through capillary scanning test (see MST optimization). The capillaries that 
is used in MST instrument is made of high pure glass with capacity about 4 μl and known as 
standard capillary. Moreover, coated capillaries are available as a second option for sticky 
samples, if the sample sticking was occurred. The capillary tray is loaded with16 different sam-
ples in each experimental measurement. Virtually, MST detection can be carried out through 
either label or label free system where, several molecules/biomolecules had native fluoro-
phores in UV region such as presence of tryptophan in protein which have excitation wave-
length at 280 nm and emission wavelength at 360 nm. MST label free system can be used 
whenever the fluorescence signals of intrinsic fluorophores are sufficient to be detected other-
wise, labeling is the best choice for MST measurements. Furthermore, if both partners have 
intrinsic fluorophores, one partner should be distinguished for measuring in specific wavelength 
range without overlapping from the second [128]. For the experiments that use labels, MST 
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instrument contains three types of LED filter combinations: blue (excitation 460-480 nm, emis-
sion 515-530 nm), green (excitation 515-525 nm, emission 560-585 nm) and red (excitation 
605-645 nm, emission 680-685 nm). There are wide range of detection wavelengths depend 
on the dyes that used for labeling of one partner. Moreover, high-affinity interactions with a 
sub-Nanomolar scale preferred to carry out in red visible zone using red dyes to improve the 
sensitivity in low-picomolar concentrations [127]. 
2.2.1.4.2. Samples preparation  
One of MST advantages is the very low sample consumption. The samples might be prepared 
in microliter of volume range ~20 μl and the capillary volume is about 4 μl while, thermophoresis 
occurrs in about 2 nl of capillary sample volume. MST measurements is taking place through 
the titration of serial concentration of nonfluorescent partner against fixed concentration of flu-
orescent partner. The samples can be prepared through serial dilution procedures as shown 
in the general scheme (Fig.18). 
 
Figure. 18. General scheme for MST sample preparation. 
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Furthermore, the minimum and maximum sample concentrations are determined according to 
the titrated partner (nonfluorescent molecule) where the minimal concentration should be suf-
ficiently low to measure unbound state and maximum concentration should be 40-fold above 
the dissociation constant to reach the saturation [100,127]. MST allow to use buffers without 
restrictions however, the concentration of the buffer should be kept constant as well as the 
solvent that is used to dissolve some analytes especially small molecules such as ethanol, 
methanol, dimethyl sulfoxide (DMSO), etc. Buffer additives such as the detergents and the 
sample stabilizers might be used as well [122].  
By contrast, the labeling procedures is necessary to provide high sensitivity and selectivity in 
fluid mixture therefor, most MST approaches have been carried out with labeling technique to 
avoid high background of UV fluorescence that exist in bioliquid samples such as cell lysate 
and blood serum [100]. Usually, protein labeling can be implemented via using crosslinker 
reactive group which covalently binds to specific functional group of protein after coupling of 
fluorescent dye such as N-hydroxysuccinimide and maleimide. This labeling approach is need 
for the washing step to remove unreacted dyes before MST measurements [129–131]. Alter-
natively, using of fluorescent protein such as green fluorescent protein via direct fusion to the 
targeted biomolecules can be applied [132]. 
The labeling approaches are crucial to obtain highly sensitive and selective measurements 
although the presence of labels at random position has no influence on thermophoresis [100]. 
2.2.1.4.3.  MST method optimization 
The optimization of MST experiment is substantial to produce valuable measurements of bind-
ing events. Therefore, MST instrument offers optimization steps before the measurements in-
cluding fluorescence test and capillary scanning test to minimize experimental errors such as 
sample pipetting, sample sticking, low/high fluorescence intensity and suboptimal concentra-
tion range. Furthermore, MST signals might indicate some problems such as protein aggrega-
tion during the assay. Fluorescence scanning test is the first pretest to perform for one time at 
the beginning of MST experiment because it is important to optimize the fluorescence intensity 
of fluorescent partner and to avoid such background fluorescence resulted from sample mix-
ture and to select the proper concentration of fluorescent partner which can give sufficient 
signal. Fluorescence pretest is carried out through selecting three different concentrations of 
fluorescent partner, buffer sample without any reactant partners, and the non- fluorescent part-
ner.  
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The second pretest is capillary scanning test which is performed at the beginning of each sam-
ple measurement to provide indication about variations in fluorescence intensity between the 
samples which might be attributed to handling errors or sample sticking to the capillary wall as 
shown in Fig 19.  
 
Fig. 19. Capillary scanning test where, sample sticking could be detected through peak 
shape and intensity [127]. 
Furthermore, there is one important indicator that can be obtained from MST signals whereas, 
the signal shape can be distorted due to sample aggregate (Fig.20). In this case new sample 
preparation is recommended with different buffering system or by adding buffer additives to 
inhibit sample aggregates. 
 
Fig. 20. MST signals for Sample aggregates (left) in comparison with normal MST  
              signals (right) [127]. 
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Therefore, the good sample preparation is a critical factor in MST experiment and many ex-
perimental errors are related to poor sample preparation and handling. In this context, trouble-
shooting of several MST analytical errors and suggested optimum steps are summarized in 
Table 4 [100,124,127].  
   
Table 4. Troubleshooting of MST analytical errors 
Problem Indication Optimization 
Sample adsorption - Asymmetric peak in capil-
lary scanning. 
- Instable fluorescence in-
tensity for the same sam-
ple over the runs. 
- Fluorescence drop along 
titration curve. 
-  Using coated capillaries. 
-  Using buffer additives. 
 
Sample aggregation - MST signals show bumps 
or waves. 
- MST signals strongly de-
viated. 
 
- Spinning down the sam-
ple before the experi-
ment. 
- Using buffer additives. 
- Buffer optimization. 
Concentration error -   No binding saturation has    
been obtained. 
-  Unable to quantify un-
bound state. 
-   Optimize the concentration       
range to be wider. 
Pipetting errors - Peak intensity in capillary 
scanning is deviated. 
- Use correct pipetting 
technique. 
Low signal to noise ratio - MST signals not discrimi-
nated from background 
fluctuation. 
- Increase IR laser power. 
- Spinning the sample. 
- Increase the activity of 
the fluorescent sample. 
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3. Materials and methods 
3.1. Deferiprone-Iron (III) separation and interaction studies 
3.1.1. LC/MS method  
3.1.1.1. Chemicals and reagents 
Deferiprone, ferric chloride hexahydrate FeCl3.6(H2O) were purchased from Sigma Aldrich 
(Steinheim, Germany). Ammonium hydroxide, methanol, ammonium formate (HPLC grade), 
and sodium hydroxide (analytical grade) were purchased from Merck (Darmstadt, Germany). 
PTFE filters (0.2 µm) were obtained from Agilent (Agilent Technologies, Germany). Ultra-pure 
water (resistivity > 18 MΩ.cm−1 at 25°C and TOC < 5 ppb) was obtained from AriumTM pro 
ultrapure water system (Sartorius, Goettingen, Germany). 
3.1.1.2. Instrumentation 
Chromatographic analyses were performed using Agilent 1200 LC/MS system (Agilent Tech-
nologies, Waldbronn, Germany) equipped with a quaternary pump, autosampler with controlled 
tray thermostat, column heater, and photodiode array detector as well as 6120 series single 
quadrupole mass spectrometer (Agilent Technologies, Waldbronn, Germany). All data pro-
cessing was carried out using Agilent Chemstation software (Agilent Technologies, Waldbronn, 
Germany). 
3.1.1.3. LC/MS conditions 
Chromatographic separation was achieved on high-resolution monolithic column ChromolithTM, 
Speed ROD RP-18e (100 mm x 4.6 i.d.) made from a single rod of high-purity monolithic silica, 
(Merck, Darmstadt, Germany) equipped at room temperature (25°C). The stationary phase is 
stable within a pH range from 2.0 to 8.0. The mobile phase was pumped with a gradient elution 
program using three lines (A- ammonium formate buffer (pH 7.4; 10 mM), B- water, and C- 
10% methanol) and was delivered at a flow rate of 1.0 mL min−1 according to the following 
programs: 0.0–0.5 min (10% A, 80% B), 0.5–2.5 min (10% A, 70% B), 2.5–3.0 min (80% A, 
10% B), 3.0–4.5 min (70% A, 20% B), and 4.5–5.5 min (10% A, 80% B). Each component of 
the mobile phase was degassed before use in an ultrasonic bath for 10 min. Ionization was 
conducted in the positive mode with a gas temperature of 350°C, a nebulizing gas pressure of 
35 psi, a capillary voltage of 3000 V, and a fragmentor voltage of 100 V for each analyte. 
Nitrogen was used as both nebulizer and drying gas at a flow rate of 10 L min−1. MS identifica-
tion was performed under mass scanning mode which allows working in a mass range from 10 
to 1500 m/z ratio. 
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3.1.1.4. Samples preparation 
In the LC/MS method, the primary stock solution of CP20 (10 mM) was prepared in water by 
dissolving 0.0139 g in a 10 mL volumetric flask. Further dilutions were conducted to prepare 
0.5, 0.7, 0.9, 1.1, 1.3, 1.5, 1.7, and 1.9 mM of standard solutions for calibration measurements. 
FeCl3.6 H2O (10 mM) stock solution was prepared by dissolving 0.027 g in water. For binding 
study, Fe/CP20 mixtures of 1:2, 1:2.8, 1:3.6, 1:4.4, 1:5.2, 1:6, 1:6.8, and 1:7.6 were prepared 
by aliquoted of a proper amount of CP20 (range of 0.5–2 mM) to mix with fixed concentration 
of Fe3+ ion (250 μM) then complete the volume with 10 mM ammonium formate buffer at pH 
7.4. All samples were left to stand for 5 min to equilibrate. The working standard solutions were 
freshly prepared every week and stored in amber bottles at 4°C. 
3.1.2. CE/FA Method 
3.1.2.1 Chemicals and reagents  
Deferiprone, ferric chloride hexahydrate FeCl3.6(H2O), and sodium tetraborate decahydrate 
Na₂B₄O₇.10(H₂O) were purchased from Sigma Aldrich (Steinheim, Germany). Sodium hydrox-
ide (analytical grade) were purchased from Merck (Darmstadt, Germany). Hydrochloric acid 
(HCl) was obtained from Fluka (Buchs, Switzerland). PTFE filters (0.2 µm) were obtained from 
Agilent (Agilent Technologies, CA, USA). Ultra-pure water (resistivity > 18 MΩ.cm−1 at 25°C 
and TOC < 5 ppb) was obtained from AriumTM pro ultrapure water system (Sartorius, Goettin-
gen, Germany). 
3.1.2.2. Instrumentation 
Electrophoretic analyses were achieved using Agilent G1600AX Capillary Electrophoresis Sys-
tem (Agilent Technologies, Waldbronn, Germany) equipped with a diode-array UV–Vis detec-
tion system. The analyses were carried out in a 75 μm I.D., 375 μm O.D. uncoated fused silica 
capillary with a length of 48.5/8.5 cm (Ltot/Leff) from Polymicro Technologies (Phoenix, AZ, 
USA) thermostated at 25°C. Data were collected and analyzed using the software ChemSta-
tion (Agilent Technologies) and Microsoft Excel. 
3.1.2.3. CE/FA conditions 
CE analyses were carried out using short-end injection mode. The samples were injected hy-
drodynamically into the capillary by placing the vial with the sample at the outlet and the vial 
with the buffer at the inlet and then by applying a negative pressure of 10 mbar for 50 s at the 
inlet. An operational voltage of 10 kV was applied in negative polarity mode, and the detection 
wavelength was set to 280 nm. Before the first use, the new capillary was conditioned by rising 
with 1 M NaOH for 20 min and then BGE for 20 min. At the beginning of each measuring day, 
the capillary was conditioned by rinsing with 1 M NaOH for 15 min followed by BGE for 15 min; 
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between runs, the capillary was conditioned by rinsing with BGE for 0.5 min, 1 M NaOH for 2.5 
min, and again BGE for 1.5 min. All rinsing steps were achieved with a pressure of 950 mbar 
at 25°C. 
3.1.2.4. Samples preparation 
All stock and sample solutions were prepared in 20 mM borate buffer which is also used as 
BGE. BGE was prepared by dissolving 0.763 gm of sodium tetraborate decahydrate 
(Na2B4O7 · 10 H2O) in 80 ml of water then adjust pH to 10.5 with 1 M NaOH. The vol-
ume was then completed to 100 ml with water. The primary stock solution of CP20 (10 
mM) was prepared in BGE by dissolving 0.0139 g in a 10.0 mL volumetric flask. Thereafter, 
further dilutions were conducted to prepare different concentrations in the range of 40–240 μM 
for calibration measurements. FeCl3.6(H2O) (100 mM) stock solution was prepared by dissolv-
ing 0.27 g into water. Every day, the stock solution was diluted with BGE to obtain 10 mM, 
which was then used for preparation of the calibration and the mixture samples. The mixed 
samples contain a final fixed concentration of Fe3+ ion (60 μM) and different concentrations of 
CP20 in the range of 60–400 μM, dissolved in BGE. The complex was left to stand for 5 min 
to equilibrate and then injected to the CE instrument. 
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3.2. Deferiprone-essential metal ions interaction studies 
3.2.1. MST Method 
3.2.1.1. Chemical and reagents 
Deferiprone, FeCl3.6(H2O), ZnCl2, NiCl2.6(H2O), MnCl2, CuCl2.2(H2O), CoCl2.6(H2O), MgCl2, 
CaCl2, 2-Amino-2-(hydroxymethyl) propane-1,3-diol (Tris) buffer were purchased from Sigma 
Aldrich (Steinheim, Germany). Hydrochloric acid (HCl), sodium hydroxide (NaOH) were pur-
chased from Merck (Darmstadt, Germany). Ultrapure water was obtained from AriumTMpro ul-
trapure water system (Sartorius, Goettingen, Germany). 
3.2.1.2. Instrumentation 
The Monolith NT.115 LabelFreeTM MST instrument (NanoTemper Technologies, Munich, Ger-
many) was used to measure the binding events. MST instrument was equipped with a capillary 
tray allowing for the successive measurement of 12 samples in each run using standard glass 
capillaries. The MST instrument was supplemented with NT Analysis software provided by 
NanoTemper Technologies.  
3.2.1.3. MST conditions 
The MST experiment was performed on a label-free system, which depends on the intrinsic 
fluorescence of one interacting partner. MST scanning was conducted first to optimize the MST 
conditions. During MST optimization, LED intensity was set at 50% excitation intensity and 
MST power at 20% power. All samples were loaded in the standard MST capillaries and the 
total analysis time for each experiment was about 10 min. For each measurement, a total laser 
on/off cycle of 35 sec was set, which involves 30 sec on and 5 sec off. Fluorescence detection 
has been carried out at excitation wavelength 280 nm and emission wavelength at 360 nm. 
3.2.1.4. Sample preparation 
 Tris buffer (0.1M) was prepared by dissolving 12.114 g of powder in water, and then adjusting 
pH to 7.4 and completing the volume with water to 1000 ml total volume using volumetric flask. 
The obtained solution was used as a diluent for further metal ions and CP20 serial dilutions. A 
solution of 1 mM of each metal ion was prepared first by dissolving a calculated amount of 
metal salts in water to ensure metal solubility, and then completing the total volume with 0.1 M 
Tris buffer to 10 ml total volume. CP20 was prepared by dissolving 0.0139 g of the standard 
powder in water to obtain 10 mM stock solution. All stock solutions were stored in a dark box 
and refrigerated at 4 oC. 
MST scanning experiment have been carried out using three different concentrations of CP20 
(500, 250, and 100 µM) and 500 µM of each metal ion were prepared by dilute aliquoted vol-
umes from stock solutions using 0.1 M Tris buffer, and the obtained solutions were used for 
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MST scanning to investigate the fluorescence activity of the interacting components. Subse-
quently, MST titration conducted by preparing 12 different samples for each measurement that 
contained CP20/metal ion complexes, whereas 100 µM of CP20 titrated against different serial 
concentrations of intended metal ions in the range from 0.048 to 100 µM. The components 
were mixed well in PCR vials using 1:1 serial dilution and left for 30 min to equilibrate before 
measuring in the MST instrument. 
 
3.2.2. ESI-MS method 
3.2.2.1. Chemicals and reagents 
Deferiprone, FeCl3.6(H2O), ZnCl2, NiCl2.6(H2O), MnCl2, CuCl2.2(H2O), CoCl2.6(H2O), MgCl2, 
CaCl2, and ammonium acetate buffer (CH3COONH4) were purchased from Sigma Aldrich 
(Steinheim, Germany). Ammonium hydroxide solution (NH4OH) 25% were purchased from 
Merck (Darmstadt, Germany). PTFE filters of 0.2 µm was obtained from Agilent (Agilent Tech-
nologies, Waldbronn, Germany). Ultrapure water was obtained from AriumTM pro ultrapure wa-
ter system (Sartorius, Goettingen, Germany). 
3.2.2.2. instrumentation 
ESI-MS analyses were performed on an Agilent 6120 single quadrupole mass spectrometer 
(Agilent Technologies, Waldbronn, Germany). The instrument was equipped with ESI source 
and processed in positive ion mode with selected ion monitoring or mass scanning, which al-
lows to work with a mass range from 10 to 1500 m/z ratio. 
3.2.2.3. ESI-MS conditions 
ESI-MS was used as a complementary technique to confirm the interaction and binding stoi-
chiometry. The samples were directly infused into the ion source through the instrument sy-
ringe pump (10 μl min−1). ESI-MS conditions were optimized as follows: Capillary voltage 3000 
V (positive polarity), drying gas temperature 300⁰C, nebulizer pressure 35 psi, and fragmentor 
voltage 100 V. 
3.2.2.4. Samples preparations 
In ESI-MS experiment, metal–CP20 complexes were prepared in a fixed ratio of 1:5 with an 
excess CP20 concentration to avoid system contamination by metal ions. Moreover, 200 µM 
of each metal ion was mixed with 1 mM of CP20, and then the volume was completed with 
ammonium acetate buffer at pH 7.4 to the total final volume of 10 ml. All samples were left in 
dark for 30 min to equilibrate. Thereafter, the samples were filtrated using PTFE 0.2 µm filter 
and injected directly to MS. 
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3.3. Deferiprone-human serum albumin interaction studies 
3.3.1. CE based methods  
3.3.1.1. Chemicals and reagents 
Deferiprone and human serum albumin (HSA) (>97%, essentially fatty acid free, lyophilized 
powder), Acetanilide were purchased from Sigma Aldrich (Steinheim, Germany). Potassium 
phosphate buffer as monobasic and dibasic, Sodium phosphate buffer as monobasic and di-
basic, were purchased from Merck (Darmstadt, Germany). sodium hydroxide (NaOH) were 
purchased from Merck (Darmstadt, Germany). Ultrapure water was obtained from AriumTM pro 
ultrapure water system (Sartorius, Goettingen, Germany). 
3.3.1.2. Instrumentation 
Electrophoretic analyses were achieved using PrinceCE-C760 Capillary Electrophoresis Sys-
tem (Prince technologies, Netherland) equipped with a diode-array UV-Vis detection system. 
The analyses were carried out in a 50 μm I.D., 360 μm O.D. uncoated fused silica capillary 
with a length of 35/25.5 cm (Ltot/Leff) (Polymicro Technologies AZ, USA) thermostated at 25°C. 
Data were collected and analyzed using Microsoft Excel. 
3.3.1.3 CE/FA conditions 
CE/FA analyses were carried out using long-end injection mode. The samples were injected 
hydrodynamically into the capillary by placing the vial with the sample at the inlet and the vial 
with the buffer at the outlet and then by applying a positive pressure of 50 mbar for 80 s at the 
inlet. An operational voltage of 15 kV was applied in the positive polarity mode, and the detec-
tion wavelength was set to 210 nm. Before the first use, the new capillary was conditioned by 
rising with 1 M NaOH for 20 min and water for 10 min then BGE for 20 min. At the beginning 
of each measuring day, the capillary was conditioned by rinsing with 1 M NaOH for 10 min, 
water 5 min, and BGE for 10 min; between runs, the capillary was conditioned by rinsing with 
1 M NaOH for 2 min, water for 1 min and BGE for 2 min. All rinsing steps were achieved with 
a pressure of 1000 mbar at 25°C. 
3.3.1.4. CE/FA samples preparations  
All stock and sample solutions were prepared in 20 mM potassium phosphate buffer which 
used as BGE through using of two potassium phosphate salts. By weighting 0.5818 gm of 
dibasic potassium phosphate buffer (K2HPO4) then dissolved in 100 ml of water and 0.0678 
gm of mono basic potassium phosphate buffer (KH2PO4) has been dissolved 100 ml of water. 
BGE was prepared in 100 ml volumetric flask by mixing of 23 ml of KH2PO4 and 77 ml of 
K2HPO4 and, adjusting the pH to 7.4. This solution has been also used as diluent for the sam-
ples. The stock solution of CP20 (10 mM) was prepared in BGE by dissolving 0.0139 g of CP20 
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in a 10 ml volumetric flask. Thereafter, further dilutions were conducted to prepare different 
concentrations in the range of 100–800 μM for calibration measurements. HSA 1 mM stock 
solution was prepared by dissolving 0.664 g of the protein in 10 ml BGE. For binding experi-
ment, different concentrations of CP20 in range of 50-700 μM have been prepared in BGE then 
150 μM of fixed concentration of HSA were added and the volume was completed to 1 ml with 
BGE. The complex was left to stand for 10 min to equilibrate and then injected in the CE capil-
lary. 
3.3.1.5 mACE conditions 
All samples have been injected through long-end injection hydrodynamically at the inlet with 
positive pressure of 50 mbar (0.5 kPa) for 5 s. An operational voltage of 10 kV was applied in 
positive polarity mode, and the detection wavelength was set to 230 nm. Before the first use, 
the new capillary was conditioned by rising with 1 M NaOH for 20 min and H2O for 10 min then 
BGE for 20 min. At the beginning of each measuring day, the capillary was conditioned by 
rinsing with 1 M NaOH for 10 min, H2O 5 min, and BGE for 10 min; between runs, the capillary 
was conditioned by rinsing with 1 M NaOH for 2 min, H2O for 1 min and BGE for 2 min. All 
rinsing steps were done with a pressure of 1000 mbar (95 kPa) at 25°C. 
3.3.1.6. mACE Samples preparations 
All stock solutions have been prepared as described in previous CE/FA methods (See section 
3.3.1.4). Additionally, Acetanilide as EOF marker was prepared by dissolving of 0.0135 gm in 
10 ml of BGE to obtain 10 mM stock solution.  
In mACE binding experiment, different concentrations of CP20 in the range of 50-400 μM have 
been prepared in BGE and injected to the CE capillary. The injected sample consisted of 75 
μM HSA and 1 mM acetanilide as EOF marker.  
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3.3.2. MST method  
3.3.2.1. Chemicals and reagents 
See section (3.3.1.1) 
3.3.2.2. Instrumentation 
The Monolith NT.115 LabelFreeTM MST instrument (NanoTemper Technologies, Munich, Ger-
many) was used to measure the binding events. MST instrument was equipped with a capillary 
tray allowing for the successive measurement of 16 samples in each run using standard glass 
capillaries. For each measurement, a total laser on/off cycle of 35 sec was set, which involves 
30 sec on and 5 sec off. The MST instrument was supported with NT Analysis software pro-
vided by NanoTemper Technologies.  
3.3.2.3. MST conditions 
The measurements have been carried out under the optimized MST conditions with LED power 
50% (excitation power) and MST power 20% (laser power to induce thermophoresis). MST 
signals was obtained thorough 35 S of time scale where set laser on for 30 S to induce thermal 
diffusion followed by 5 S laser off for back diffusion state. Fluorescence detection has been 
carried out at excitation wavelength 280 nm and emission wavelength at 360 nm. 
3.3.2.4. Sample preparation 
Standard stock solutions have been prepared in 0.1 M phosphate buffer. Where, 2.209 gm of 
dibasic sodium phosphate buffer (Na2HPO4) and 0.3394 gm of monon basic sodium phosphate 
buffer (NaH2PO4) have been dissolved in 80 ml of H2O then, adjust pH to desired pH at 7.4 
with NaOH and completed the volume with H2O to obtain 100 ml of sodium phosphate buffer 
which used as diluent for the stock samples preparations and further serial samples dilution. 
CP20 10 mM was prepared through weighting of 0.0139 gm of reference standard powder and 
dissolved in 10 ml of 0.1 M sodium phosphate buffer. While, 100 μM of HSA standard solution 
has been prepared by dissolving 0.0664 gm of HSA standard powder in 10 ml of 0.1 M sodium 
phosphate buffer.  
The working samples have been prepared according to 1:1 serial dilution of CP20 titrated part-
ner with concentration range of 48 nM to 100 μM then, the fixed concentration of 1μM of fluo-
rescent partner (HSA) has been added to each sample. The mixtures were kept stand for 10 
min in dark area to equilibrate before MST measurement.  
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3.4. Deferiprone-human lactoferrin interaction studies 
3.4.1 MST method  
3.4.1.1 Chemicals and reagents  
 Deferiprone, human lactoferrin (Lf) 98% lyophilized powder and 2-Amino-2-(hydroxymethyl) 
propane-1,3-diol (Tris) buffer were purchased from Sigma Aldrich (Steinheim, Germany). Hy-
drochloric acid (HCl), sodium hydroxide (NaOH) were purchased from Merck (Darmstadt, Ger-
many). Ultrapure water was obtained from Arium®pro ultrapure water system (Sartorius, 
Goettingen, Germany). 
3.4.1.2. Instrumentation 
The Monolith NT.115 LabelFreeTM MST instrument (NanoTemper Technologies, Munich, Ger-
many) was used to measure the binding events. MST instrument was equipped with a capillary 
tray allowing for the successive measurement of 16 samples in each run using coated capil-
laries. For each measurement, a total laser on/off cycle of 35 sec was set, which involves 30 
sec on and 5 sec off. The MST instrument was supplemented with NT Analysis software pro-
vided by NanoTemper Technologies. Fluorescence detection has been carried out at excitation 
wavelength 280 nm and emission wavelength at 360 nm. 
3.4.1.3. MST conditions 
The measurements have been carried out under the optimized MST conditions with LED power 
40% (excitation power) and MST power 20% (laser power to induce thermophoresis). MST 
signals was obtained thorough 35 S of time scale where set laser on for 30 S to induce thermal 
diffusion followed by 5 S laser off for back diffusion state. Fluorescence detection has been 
carried out at excitation wavelength 280 nm and emission wavelength at 360 nm. 
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3.4.1.4. Samples preparations 
Standard stock solutions have been prepared in 0.1 M tris buffer. Tris buffer was prepared by 
dissolving 1.2114 g of the powder in water, and then adjusting the pH to 7.4 with HCl and 
completing the volume to 100 ml with water. The obtained solution was used as a diluent for 
further stock and samples serial dilutions. CP20 10 mM was prepared through dissolving 
0.0139 gm of the reference standard powder in 10 ml of 0.1 M tris buffer. While, 100 μM of Lf 
standard solution has been prepared by dissolving 0.084 gm of Lf standard powder in 10 ml 
0.1 M tris buffer then, further dilution was made to reach 1 μM Lf standard solution. 
The working samples have been prepared according to 1:1 serial dilution of CP20 titrated part-
ner in a concentration range of 7 nM to 250 μM then, the fixed concentration of 120 nM of 
fluorescent partner (Lf) has been added to each sample. The mixtures were kept stand for 10 
min in dark area to equilibrate before the MST measurement.  
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4. Results and Discussion 
4.1. Deferiprone-iron (III) separation studies 
4.1.1. LC/MS method  
Analysis of metal complexes using LC is challenging because of weak system stability and 
possible dissociation of the complex during separation. This separation is of particular concern 
for complexes with weak binding affinities. However, the CP20-Fe binding system is relatively 
stable because Fe3+ is a hard Lewis acid that forms stable complexes over a wide pH range. 
The concentrations of Fe3+ and CP20 are critical for system stability because of the low den-
ticity of CP20; therefore, in extremely dilute solutions (<106 M), the Fe(CP20)3 complex is prone 
to dissociation [12,13]. Thus, the concentrations of the working solutions were kept close to 
the millimolar range (103 M). Moreover, adding excess amounts of CP20 to the solution is 
necessary to maintain the equilibrium state. All chromatographic separations were performed 
at pH 7.4 to ensure that the system resembled physiological conditions as well as the stability 
of the complex during separation in the LC system. Under chromatographic conditions consist-
ing of a mobile phase (10 mM ammonium formate:methanol 60:40) in isocratic elution, a high-
resolution C18 monolithic column as the stationary phase under a controlled temperature at 
25°C, and a flow rate of 1 ml/min, CP20 was determined successfully (Fig. 21 A). However, 
partial separation was obtained for the Fe(CP20)3 complex (Fig. 21 B). Furthermore, mobile 
phase manipulations involving an increase or decrease in the organic modifier did not yield 
improvements in resolution between free CP20 and the Fe(CP20)3 complex. Increasing the 
amount of methanol led to a decrease in separation and the analytes were eluted at the same 
retention time, whereas decreasing the amount of methanol led to improved separation. How-
ever, no complete separation was achieved. Replacement of methanol with acetonitrile as an 
organic modifier produced co-elution of many relevant peaks with CP20. Therefore, isocratic 
elution using a binary mixture of NH4HCO2 buffer and methanol as an organic modifier could 
be used to determine CP20, but it was not capable of yielding full separation between CP20 
and its Fe(CP20)3 complex.  
The relevant peaks for both CP20 and the Fe(CP20)3 complex were confirmed via MS scan-
ning in the positive ion mode. A base peak at m/z 140 represented CP20, whereas a complex 
was formed at m/z 471.1, which represented the Fe(CP20)3 complex. Furthermore, one signif-
icant peak at m/z 332, which represented the Fe(CP20)2 complex, was formed in the medium 
and detected via the MS detector (Fig. 21 C).  
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In addition, the UV spectrum pattern was characteristic for the complex, including the presence 
of a broad absorption band at a maximum intensity of 450 nm. This band did not exist for CP20, 
confirming that the method achieved satisfactory discrimination between CP20 and its iron 
complex (Fig. 21 D and E). 
 
 
Fig. 21. LC chromatogram of CP20 (A), CP20 and the Fe(CP20)3 complex using isocratic 
elution order (B). MS spectra of CP20 and its iron (III) complexes (C). UV spectra 
of free CP20 (D) and the Fe(CP20)3 complex (E). 
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To improve chromatographic resolution between CP20 and the Fe(CP20)3 complex, LC sepa-
ration was investigated under different temperatures (25, 30, 37, and 40°C). As shown in Fig. 
22, insignificant changes in complex formation were observed in response to temperature in-
creases, whereas CP20 tended to form complexes at physiological temperatures. Conversely, 
the temperature changes did not improve separation between CP20 and the Fe(CP20)3 com-
plex.  
 
 
Fig. 22. Effect of temperature on CP20 and Fe(CP20)3 complex formation. 
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To achieve complete separation between free CP20 and the Fe(CP20)3 complex, isocratic 
elution was replaced with gradient elution using a mobile phase consisting of three compo-
nents: (1) 10 mM NH4HCO2 buffer; (2) H2O; and 10% methanol. The successful separation of 
free CP20 from the Fe(CP20)3 complex might be attributable to the addition of a high water 
ratio (80%) and decreasing the methanol content to 10% in comparison to the composition of 
the isocratic elution. Obviously, the gradient system led to changes in the elution order for 
CP20, which was eluted before the Fe(CP20)3 complex (Fig. 23). 
 
 
 Fig. 23. LC chromatogram for the separation of CP20 and Fe(CP20)3 complex using 
              gradient elution.  
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Under these optimal conditions, a partial method validation was performed for the sample con-
taining only CP20 without Fe3+ for calibration dependencies such as linearity, accuracy, re-
peatability, limit of detection (LOD), and limit of quantitation (LOQ), which were calculated from 
the calibration curve. Table 5 lists the parameters used in method validation for the LC/MS 
systems. 
 
 
  
Table 5. Validation parameters of the developed LC/MS method 
Detection UV detection 
280 nm 
MS detection 
m/z 140.1 for [CP20 + H]+ 
m/z 332.1 for [Fe(CP20)2]+ 
m/z 471.1 for [Fe(CP20)3]+ 
Linearity range 0.5–2 mM 
Regression equation y = 0.3825x − 60.536 
Correlation coefficient 0.998 
Repeatability (RSD%) <1.3 
**LOD 17 μM 
***LOQ 53 μM 
*RSD is the relative standard deviation, which is defined as SD/mean × 100 (n = 3). 
** LOD is the limit of detection, which is defined as (3.3 × σ/slope).  
*** LOQ is the limit of quantification, which is defined as (10 × σ/slope).  
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4.1.2. CE/FA method  
In the CE system, the separation strategy is different from that of LC. The strategy depends on 
the separation of different ionizable molecules when traveling through the electrical current. 
Thus, several challenges were encountered when considering the separation of CP20. CP20 
is a neutral molecule over a wide pH range (3.5–9.7). Thus, analysis at a physiological pH of 
approximately 7.4 is not possible using CE/FA techniques without modifying the system and 
adding additives to the background electrolyte (BGE), which complicates the system and po-
tentially affects complex formation. Moreover, the complex is stable under varying neutral and 
alkaline pH conditions [12,13]. For this reason, the CE/FA study was performed in a borate 
buffer at pH 10.5, which permitted the maintenance of a stable complex and simultaneously 
stabilized the peak plateau of free CP20 (Fig. 24).  
 
 
 
Fig. 24. CE/FA electropherogram of Fe-(CP20)3 complex and free CP20. 
 
Therefore, numerous washing procedures can be implemented to obtain a stable electropher-
ogram with sufficient separation between free drug and the complex, thereby enabling proper 
estimation of the binding events. The rinsing protocol was performed using 1 M HCl, 0.1 M 
EDTA, 1 M NaOH, H2O, and 20 mM borate buffer as a BGE. However, rinsing with EDTA 
worsened the electropherogram and led to distortion of the complex peak plateau. Moreover, 
the rinsing protocol using 1 M HCl in addition to NaOH was unsuitable, and lower peak reso-
lution was obtained. Optimized rinsing procedures were obtained using 1 M NaOH for 2.5 min 
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followed by BGE for 1.5 min as a pre-run conditioning procedure and then flushing with BGE 
for 0.5 min as a post-run rinsing procedure (Fig. 25).  
 
 
 
Fig. 25. CE/FA electropherograms for different capillary flushing procedures.  
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Moreover, a large plug injection using 10 mbar for 50 s is sufficient to keep the system in 
equilibrium in comparison to a small plug injection using 10 mbar for 5 s, which caused a 
decrease in the system’s stability and affected the result’s reproducibility. A short-end injection 
was applied using negative polarity, which proved sufficient for achieving peak separation with 
a short surface contact (~8.5 cm) in the CE/FA separation mode. The optimal applied voltage 
was 10 kV, which was obtained through manipulation at several applied voltages (5–15 kV) in 
the negative polarity mode. Because of the increase in applied voltage, the migration time and 
resolution decreased for the free drug and complex peaks (Fig. 26). 
 
 
 
 
Fig. 26. Effect of different applied voltages on the separation of free CP20 from the  
 Fe(CP20)3 complex.  
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The developed method was partially validated for linearity, accuracy, and repeatability. Method 
linearity and accuracy were assessed using samples containing only CP20 without Fe3+. More-
over, the repeatability test result was estimated as RSD%, whereas LOD and LOQ were cal-
culated from the calibration curve. Table 6 lists the parameters under which the method was 
validated for the CE/FA systems. 
 
 
 
4.1.3. Estimation of binding events from separative methods 
Estimation of the binding events for LC/MS and CE/FA data was performed using the same 
principle used to determine the free CP20 concentration. Both LC/MS and CE/FA successfully 
achieved good separation of free CP20 from the Fe(CP20)3 complex with good reproducibility. 
The binding events were determined as the association constant (Ka), and all binding param-
Table 6. Validation parameters of the developed CE/FA method 
Detection UV detection 
280 nm 
Linearity range 40–240 μM 
Regression equation y = 0.0175x + 0.3774 
Correlation coefficient 0.9986 
Repeatability (RSD%)  <4.33  
**LOD 7.9 μM 
***LOQ 24.0 μM 
*RSD is the relative standard deviation, which is defined as SD/mean × 100 (n = 3). 
** LOD is the limit of detection, which is defined as (3.3 × σ/slope). 
*** LOQ is the limit of quantification, which is defined as (10 × σ/slope). 
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eters were calculated using a nonlinear least-squares analysis (see section 2.1.3). Further-
more, the LC/MS method was performed using a binding constant of LogKa = 8.3 ± 0.17 and 
precision of RSD% <2.06 (Fig. 27 A). Meanwhile, the CE/FA method was optimized to estimate 
the binding constant as LogKa = 10.48 ± 0.12, which was in agreement with the reported values 
in the literature [12,13] with good precision as RSD% of <1.17 (Fig. 27 B).  
 
Fig. 27. Binding curves for the Fe-CP20 interactions, (A) Representative data obtained 
from the LC/MS, (B) Representative data obtained from the CE/FA. 
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Furthermore, the numbers of binding sites, ni, were estimated to be 3.40 ± 0.65 and 3.04 ± 
0.10 for the LC/MS and CE/FA systems, respectively. This finding approximately reflects the 
binding ratio in 1:3 Fe:CP20 stoichiometry, as confirmed using the MS detector in the LC/MS 
method. The estimated values of LogKa and ni are summarized in Table 7. 
The variations in the estimated binding constants between the two methods might be attribut-
able to the use of different methods; thereby, numerous parameters, such as pH, the buffering 
system, and separation mechanism, could affect the binding. Although LC/MS is an attractive 
technique that provides direct information about the binding stoichiometry, it is not ideal for 
estimating the binding events because of the lack of complex stability during LC separation. 
Moreover, the method was less sensitive because a millimolar concentration range was used 
in comparison to micromolar range for the CE/FA method.  
 
Table 7. Summary of the binding parameters for CP20 and its iron complex obtained 
using LC/MS and CE/FA methods  
Methods 
 
LogKa ± SD LogKa repeat-
ability (RSD%) 
ni ± SD Literature val-
ues 
LC/MS 8.31 ± 0.17 2.06  3.40 ± 0.65  
10.11 [12,13] 
CE/FA 10.48 ± 0.12 1.17  3.04 ± 0.10 
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4.2. Deferiprone-essential metal ions interaction studies 
4.2.1. MST and ESI-MS methods 
The chelation selectivity is considered a major concern in chelation therapy. Thus, the ideal 
chelator should selectively bind with the targeted metal without affecting other essential metals 
[15]. In this regard, an additional step was included to evaluate the interaction of CP20 with the 
most important essential metal ions. However, this type of interaction is weak, and it cannot be 
achieved via using the separation techniques. Therefore, this study was designed to evaluate 
the use of MST for the rapid screening of the interaction of CP20 with essential metal ions. It 
is worth noting that the presence of the intrinsic fluorescence of CP20 has not been previously 
reported. Meanwhile, the intrinsic fluorescence of CP20 allowed the use of label-free MST. The 
pre-test MST scan indicated that CP20 was fluorescent at concentrations ≥100 μM; therefore, 
the fixed concentration of the fluorescent partner was 100 μM, which produced a sufficient 
fluorescence signal. Different concentrations of essential metal ions were prepared and titrated 
against the fixed concentration of CP20. The binding affinity of CP20 for essential metal ions 
varies widely. CP20 exhibited significant binding to Fe3+, Cu2+, Zn2+, Co2+, and Ni2+ (Fig. 28).  
 
Fig. 28. Saturation curves for CP20 with different metal ions. The green curve represents 
Ni2+ ions, the brown curve represents Zn2+ ions, the blue curve represents Cu2+ 
ions, the gray curve represents Co2+ ions, and the red curve represents Fe3+ 
ions.  
  
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
In this study, Fe3+ (Fig. 28 red) was more likely to bind to CP20 because of the higher 
oxidation state, which featured a hard Lewis acid, in comparison to other divalent 
metal ions, and the estimated EC50 of this interaction was the lowest among the metal 
ions (20 ± 3.34 µM). Table 8 presents a summary of the MST results for CP20 with 
the tested essential metal ions. 
 
Table 8. MST binding parameters for CP20 with essential metal ions 
Metal ion EC50± SD a Hill Coefficient b 
Fe3+ 
20.6 ± 3.34 
1.50 
Cu2+ 
38.1 ± 3.39 
3.19 
Zn2+ 
39.5 ± 4.90 
1.48 
Co2+ 
51.1 ± 6.86 
1.56 
Ni2+ 
101.1 ± 22.70 
1.81 
Mn2+ - - 
Mg2+ - - 
Ca2+ - - 
a EC50 is defined as the concentration of the half-maximal response. 
          b Hill coefficient was calculated using equation (6) in section 2.2.1.3. 
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Meanwhile, the ESI-MS results indicated that theCP20 alone displayed a 100% base peak at 
m/z 140 (Fig. 29 A) while, the Fe(CP20)3 complex was formed at m/z 471, confirming the bind-
ing stoichiometry for the complex in a 1:3 Fe:CP20 ratio with a significant relative abundance 
of 25%. Concomitantly, another molecular ion peak with a relative abundance of 10% was 
noted at m/z 332. This peak represented the Fe(CP20)2 complex, and minor dissociation might 
have occurred under MS condition (Fig. 29 B). 
 
 
Fig. 29. MS spectra for free CP20 (A). MS spectra for Fe(CP20)2 at m/z 332 and Fe(CP20)3 
at m/z 471 (B). 
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The divalent metal ions exhibited different interaction behaviors with CP20. Cu2+ (Fig. 28 blue) 
and Zn2+ (Fig. 28 brown) have similar affinities for CP20 under MST conditions with estimated 
EC50 values of 38.17 ± 3.39 and 39.51 ± 4.90 µM, respectively. In comparison to Fe3+, a 2-fold 
excess was needed to achieve a half-maximal effect, reflecting the tendency of CP20 to more 
readily bind with Fe3+ than with Cu2+ and Zn2+. However, the ESI-MS results for the Cu2+ and 
Zn2+ complexes illustrated that Cu2+ formed a stable Cu(CP20)2 complex at m/z 340 with a 
relative abundance of 6% (Fig. 30 A), whereas the Zn(CP20)2 complex was formed at m/a 341 
with a 1.5% relative abundance (Fig. 30 B).  
 
 
Fig. 30. MS spectra of the Cu(CP20)2 complex at m/z 340 (A) and Zn(CP20)2 complex at 
m/z 341 (B). 
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Indeed, the MST and ESI-MS results confirmed that Cu2+ and Zn2+ are more affected by CP20 
chelation among divalent metal ions, and this finding is consistent with previous reports 
[9,12,133]. However, in vivo Zn2+ depletion is more obvious and clinically documented [38,134] 
than depletion of Cu2+. Therefore, Zn2+ levels should be monitored, although Cu2+ is predicted 
to perturb Fe3+ speciation during CP20 treatment. On the contrary, Co2+ (Fig. 29 gray) and Ni2+ 
(Fig. 29 green) exhibited weak binding affinity for CP20 in comparison with the affinities of Cu2+ 
and Zn2+. Although both metal ions displayed higher oxidation states and exhibited similar 
binding values as Zn2+ in a previous study [9], the MST results illustrated that a 2.5-fold excess 
of Co2+ was needed to achieve the Fe3+ EC50 (51.10 ± 6.86 µM), whereas a 5-fold excess was 
needed to achieve that of Ni2+ (101.09 ± 22.70 µM). Moreover, both Co2+ and Ni2+ formed weak 
complexes with CP20 with a relative abundance of <1.5% (Fig. 31 A and B). Therefore, the 
chelation effect of CP20 on Co2+ and Ni2+ is limited in comparison to that on Zn2+ and Cu2+. 
This conclusion is consistent with a previous study that evaluated Co2+ and Ni2+ complex sta-
bility with CP20 and other synthesized hydroxypyridinones [135]. 
 
Fig. 31. MS spectra for the Co(CP20)2 complex at m/z 336.1 (A) and Ni(CP20)2 complex         
at m/z 335.0 (B). 
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Table 9 summarizes the m/z values for the investigated metal ion complexes based on positive 
ion mode scanning.  
 
 
Mn2+ (Fig. 32 blue), Mg2+ (Fig. 32 brown), and Ca2+ (Fig. 32 green) did not exhibit any binding 
affinity for CP20 under the optimized MST conditions. Furthermore, the ESI-MS results con-
firmed that Mg2+ and Ca2+ do not form complexes with CP20.  
Table 9. ESI-MS data for CP20 and different essential metal ions 
Metal ion Molecular weight 
(g/mol) 
Ligand Molecular weight 
(g/mol) 
m/z ratio 
Ni2+ 58.69 CP20 139.1 335 
Zn2+ 65.38 341 
Cu2+ 63.54 340 
Co2+ 58.93 336 
Fe3+ 55.84 332, 471 
Mn2+ 54.93 331 
Mg2+ 24.30 300 
Ca2+ 40.07 316 
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Fig. 32. Representative figure for nonbinding metal ions. Green dots represent Ca2+ ions, 
brown dots represent Mg2+ ions, and blue dots represent Mn2+ ions.  
 
However, Mn2+ exhibited a different behavior in ESI-MS, producing a stable Mn(CP20)2 com-
plex at m/z 331 with a high relative abundance of 18% (Fig. 33). The different behavior of Mn2+ 
between MST and ESI-MS might be attributable to the experimental conditions of MST that 
prevent metal-ligand speciation in contrast with ESI-MS, which allowed CP20 to form a com-
plex with Mn2+ the under gas phase state. 
 
Fig. 33. MS spectra of the Mn(CP20)2 complex at m/z 331.  
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4.3. Deferiprone-protein interaction studies  
4.3.1. Deferiprone-human serum albumin interaction studies 
4.3.1.1. MST method  
In this study, the MST method was developed to quantify the binding events of CP20 with HSA. 
MST scanning was conducted for three different concentrations of CP20, HSA, H2O, and phos-
phate buffer. Strong fluorescence signals were obtained for HSA depending on the intrinsic 
fluorophores present, such as tryptophan or tyrosine residues within the protein. MST meas-
urements were recorded using a label-free MST system without the need for invasive proce-
dures via protein labeling because the fluorescence signals obtained from CP20 and HSA are 
dissimilar. The signal obtained with 1 μM HSA was 10-fold larger than that obtained with 100 
μM CP20. Thereafter, CP20 was serially diluted from 100 μM to 48 nM using a 1:1 dilution ratio 
titrated against a constant HSA concentration of 1 μM. Furthermore, no sample adsorption was 
indicated through capillary scan testing. The fluorescence intensity deviation for all measure-
ments was within the limit of <10%. 
The data were analyzed directly using Nanotemper software to obtain the binding curve. The 
obtained MST data was fit with the Kd calculation model (Fig. 34) and estimated as LogKa = 
4.3 ± 0.59. The estimated binding constant using the MST method was in accordance with the 
previous published values [64]. The binding constants are summarized in Table 10 for all ex-
periments concerning CP20-protein interactions.
 
 Fig. 34. The binding curve of CP20-HSA interaction using MST. 
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4.3.1.2. CE methods 
The CE technique is characterized by the presence of several analytical modes for studying 
drug-protein interactions. This feature makes CE-based methods superior to all separative an-
alytical techniques. In this approach, two CE modes were used to characterize the CP20-HSA 
interaction. 
4.3.1.2.1. CE/FA mode  
The CE/FA method was developed to characterize the CP20-HSA interaction. This mode was 
selected because it provided a highly stable system and it was robust CE mode for drug-protein 
interactions (see Table 1). 
Under the optimal CE conditions as described in section 3.3.1.3, partial separation of CP20 
from HSA was achieved through the formation of peak plateaus for CP20 and HSA as shown 
in Fig. 35. During the development of this method, the pre-equilibrated sample consisting of 
150 μM HSA and 500 μM CP20 was injected for different time intervals (20–80 s) at 50 mbar. 
The frontal analysis system was obtained by injection a large plug sample for 80 s at 50 mbar. 
In this analysis, the binding equilibrium was maintained, and the binding events could be esti-
mated.  
 
Fig. 35. Overlaid CE/FA electropherograms for CP20 and HSA, in which CP20 was in-
jected at different concentrations (200, 400, 600, and 700 μM).  
 
  
71 
 
 
Meanwhile, CP20 at pH 7.4 is a neutral molecule; therefore, it is useful as an EOF marker for 
the CE system to monitor run-to-run variability. The binding events were estimated using an 
external CP20 calibration curve over a linear range (100–800 μM), and the drug-bound fraction 
was calculated by subtracting the free drug concentration that was obtained as an experimental 
response from the total drug concentration. The binding constant was estimated using nonlin-
ear least-squares regression (see section 2.1.3), and a binding curve was obtained as pre-
sented in Fig 36. The binding constant was estimated as LogKa = 5.3 ± 0.28, and the number 
of binding sites was estimated as ni = 3.2 ± 2.0. All measurements were performed in triplicate.  
 
 
 
   
Fig 36. The binding curve of CP20-HSA using the CE/FA mode. 
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4.3.1.2.2. mACE mode 
The mACE mode was selected in addition to the CE/FA mode as a comprehensive technique 
for studying the CP20-HSA interaction for several reasons as follows: (1) it has been widely 
and successfully used in the study of drug-protein interactions; (2) the instrumental response 
for estimating binding events was different from that of CE/FA, thereby presenting a different 
view of the binding system; and (3) it is extremely sensitive to weak interactions, and it can 
measure minute changes of the migration time up to 0.1 s [88,96,136]. In this approach, differ-
ent CP20 concentrations were loaded into the capillary, and HSA was injected as the sample. 
This situation is opposite to the usual one because the mobility of CP20 is equal to that of the 
EOF marker, as both are neutral and have the same migration time. Moreover, HSA is charged 
at pH 7.4, and it could have been affected by its interaction with CP20 interactions because 
the mobility of HSA may have shifted. The capillary was pre-conditioned with different CP20 
concentrations ranging from 50 to 400 μM and a fixed HSA concentration of 75 μM. The sample 
was mixed with 1 mM acetanilide acting as the EOF marker. The mobility of HSA shifted be-
tween 0.1 and 0.4 s in response to the macromolecular mobilities under the defined electrical 
field. This setup was sufficient to reveal the binding between CP20 and HSA as shown in Fig. 
37. 
 
Fig. 37. mACE electropherogram for HSA and acetanilide (EOF marker) in the presence 
(green) and absence of CP20 (red). 
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The HSA mobility ratio (R) was calculated according to the relationship R = teof/tprot, in which 
teof and tprot were the migration times for the EOF marker (acetanilide) and HSA, respectively. 
These mobilities were calculated in the absence of CP20 and represented as Rf and Ri ratios. 
The binding constant was calculated using nonlinear regression as shown in Fig. 38. Moreover, 
Rc ratios were calculated at the saturated protein concentrations at which a protein’s mobility 
did not change with an increase in the drug concentration. The binding constant was estimated 
as LogKa = 4.4 ± 0.54, and all measurements were obtained in triplicate.  
 
 
 
Fig. 38. Binding isotherm for the CP20-HSA interaction obtained in the mACE mode. 
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4.3.2. Deferiprone-human lactoferrin interaction studies  
4.3.2.1. MST method  
The MST method has been implemented successfully to quantify binding between CP20 and 
Lf. A challenging point for quantifying binding using CE-based methods was strong protein 
adsorption to the capillary wall. This problem has previously been reported [137]; therefore, Lf 
is usually separated under micellar electrokinetic chromatography (MECK) conditions. This 
method was conducted using surfactant additives. This approach could interfere with its inter-
acting partners, especially Lf, because it is a highly positively charged molecule at physiologi-
cal pH, at which nonspecific interactions could occur. The MST method is considered nonin-
vasive and capable of quantifying the binding parameters under similar native conditions. Dur-
ing MST scanning, Lf exhibited extremely strong fluorescence signals in comparison to those 
of HSA, which might be attributable to the number of tryptophan residues because Lf contains 
nine tryptophans, versus only one in HSA. Therefore, the proper concentration for obtaining 
sufficient fluorescence signals was 120 nM, which was selected as the fixed Lf concentration 
in the role of the fluorescent partner. Conversely, CP20 was prepared at different concentra-
tions in the range of 7 nM to 250 μM. The MST data was fit with the Kd model. The binding 
isotherm is shown in Fig. 39.  
 
Fig. 39. The binding curve of the CP20-Lf interaction using the MST method. 
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4.3.3. Discussion of deferiprone-protein interactions 
The CP20-HSA interaction was previously investigated via spectroscopic techniques aided by 
molecular docking software [64]. Affinity-based CE approaches are widely used in drug-protein 
interaction studies. In addition, the unique MST technique has gained popularity for use in 
characterizing biomolecular interactions. Therefore, the MST and CE techniques were used to 
investigate CP20-protein interactions, and the results were compared with those obtained us-
ing previously reported methods. Regarding the present approaches, MST is considered a 
noninvasive method, and its experimental procedures are easier to implement than those of 
CE because CE optimization is required before obtaining binding measurements to ensure 
good reproducibility. However, the CE technique remains a powerful technique for character-
izing binding parameters because of the presence of several CE modes that can fit a wide 
range of binding systems. Moreover, more information, such as multi-equilibrium systems, 
binding stoichiometry, and equilibrium kinetics, could be obtained from affinity-based CE ap-
proaches.  
In the first approach for characterizing CP20-HSA interactions, both methods were capable of 
estimating the binding constant. The MST-based result estimated the binding constant as 
LogKa = 4.3 ± 0.59, which is in greater agreement with the reported values obtained by Dorraji 
et al. (LogKa = 4.0 ± 0.004) than those obtained using CE approaches, which estimated the 
binding constants as LogKa = 5.3 ± 0.28 and 4.4 ± 0.54 for CE/FA and mACE modes, respec-
tively. MST is superior to the CE technique with respect to analysis time, simple data pro-
cessing, and simple optimization procedures, whereas CE/FA approaches introduce infor-
mation about binding stoichiometry. In the CE approaches, the CE/FA and mACE modes are 
in agreement with each other, but the mACE value was closer to the reported value and the 
MST value. Repeatability was calculated as RSD% (<4.5) of the binding constant for three 
measurements (n = 3), whereas the repeatability of CE/FA expressed as the RSD% of the 
binding constant for the three measurements was <5.3%. 
In the second approach, MST and CE were used to characterize the CP20-Lf interaction. CE 
approaches failed to determine Lf binding despite the use of several optimization procedures 
because of the high protein adsorption on the capillary wall. MST successfully determined the 
binding constant, which was estimated as LogKa = 5.0 ± 1.6. The success of the MST approach 
success might be attributable to its nature, which depends on the measurement of localized 
thermophoresis. MST is considered a good alternative technique for measuring binding events, 
especially under challenging conditions. The binding parameters for the CP20-protein interac-
tion are summarized in Table 10. 
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Table 10. Binding parameters of CP20-protein interactions 
Protein Method LogKa ni literature 
value 
 
 
HSA 
MST 4.3 ± 0.59 not possible  
 
4.0 ± 0.004 
[64] 
 
CE/FA 5.3 ± 0.28 3.2 ± 2.0  
mACE 4.4 ± 0.54 not possible 
Lf MST 5.0 ± 1.61 not possible not reported 
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5. Summary 
5.1. Deferiprone-metal ions separation and interaction studies 
Once inside the human body, drugs can bind to several biomolecules, small molecules, or even 
metal ions. Therefore, the study of drug affinity for different targets have a key role in drug dis-
covery and development. Moreover, all studies of drug pharmacokinetics/pharmacodynamics in-
cluding drug transport, metabolism, excretion, and modulating biomolecular functions involve 
estimation of the binding properties of drug toward target biomolecules to improve the under-
standing to the behavior of drugs inside the body. In this context, CP20 remains an interesting 
therapeutic molecule that can be beneficial in several clinical situations in addition to β-thalas-
semia such as neurodegenerative diseases, cancers, and infectious diseases. In the past, the 
chromatographic profile of CP20 was extremely poor because of several technical challenges 
related to the characterization of drug separation. Moreover, previously developed chromato-
graphic methods are inadequate for separating CP20 from its iron (III) complex. Conversely, 
CE-based methods were not described. Therefore, LC/MS and CE/FA methods were devel-
oped for the separation and concurrent determination of free CP20 and the Fe(CP20)3 complex 
in one run as well as characterizing drug-metal interactions. In LC/MS approaches, the drug 
was determined and separated from the complex using a monolithic column and nonlinear 
gradient elution order, which are critical for the separation of two overlapping peaks. Moreover, 
the MS detector was used to study complex formation under the optimal conditions. Subse-
quently, the CE/FA method was developed to determine CP20 and separate free CP20 from 
the Fe(CP20)3 complex. The developed CE/FA method depends on the formation of a stable 
peak plateau for the free drug that can be differentiated from the complex peak plateau, which 
moves as a bulk in the capillary to achieve binding equilibrium during the separation. The bind-
ing constant and binding stoichiometry were estimated after achieving good separation for free 
CP20 using nonlinear least square regression, after which the binding values were compared 
with the published values. In a comparison between LC/MS and CE/FA as separative methods, 
LC/MS gives direct information about the binding stoichiometry via MS screening; however, 
CE/FA is a more stable and accurate system for estimating binding parameters, in agreement 
with prior studies. Overall, both methods achieve good separation with satisfactory validity. 
Furthermore, for the interactions of CP20 with other essential metal ions that cannot be inves-
tigated using separative techniques, MST and ESI-MS methods were used to investigate these 
types of weak interactions. MST is a new technique that has been developed for characterizing 
molecular and biomolecular interactions in free solution. The interaction between CP20 and 
different essential divalent metal ions, including Cu2+, Zn2+, Co2+, Ni2+, Mn2+, Mg2+, and Ca2+, in 
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addition to Fe3+, has been studied using a label-free MST system. Whereas CP20 produces 
sufficient fluorescence signals under MST conditions, which was reported for the first time. 
Indeed, Cu2+ and Zn2+ exhibited greater tendencies to interact with CP20 among divalent metal 
ions, not as strong as that of Fe3+. Although Cu2+ and Zn2+ have similar interaction activity 
under the optimal MST conditions, Zn2+ should be monitored during CP20 treatment because 
the amount of Zn2+ are much larger than Cu2+ and Zn2+ deficiency is more observable.  
Meanwhile, Co2+ and Ni2+ display weak binding affinity for CP20, and no chelation effect for 
CP20 against these ions. Contrarily, Mg2+ and Ca2+ are the most abundant divalent essential 
metal ions in the body, and they are not affected by CP20 chelation, as confirmed by the MST 
and ESI-MS results. The MST and ESI-MS results revealed the partial selectivity of CP20 to 
more readily bind with Fe3+ than with other divalent essential metal ions, whereas Zn2+ and 
Cu2+ are more likely to be depleted in vivo during CP20 treatment.  
5.2. Deferiprone-protein interaction studies 
The interactions of CP20 with proteins have rarely been studied. Only one study described the 
interaction of CP20 with HSA. Meanwhile, study of the binding affinity of CP20 to different 
target biomolecules may provide valuable information regarding the pharmacokinetic/dynam-
ics, therapeutic effect, and toxicity of CP20. Primarily, HSA has been selected as a predomi-
nant carrier protein in plasma. MST- and CE-based methods have been developed to investi-
gate the interaction of CP20 with HSA. MST was successfully used to assess drug-metal in-
teractions and additionally used to estimate binding parameters in comparison with published 
literature values. The MST label-free system was used depending on the intrinsic fluorescence 
of HSA and then successfully applied to estimate binding parameters. Meanwhile, CE-based 
approaches enabled good comparability with MST. The CE/FA mode was used to investigate 
binding parameters via the discrimination between free CP20 as a peak plateau separated 
from the large bulk macromolecule. Therefore, the binding constant and stoichiometry have 
been easily estimated. Conversely, the mACE mode measures the mobility of HSA in the pres-
ence and absence of CP20, and the binding constant has been estimated directly based on 
the different mobilities of one partner. According to the obtained results, MST was superior 
because of the short analysis time, low sample consumption, and easy optimization proce-
dures. Moreover, MST enabled automated scanning for system diagnosis. All of the developed 
methods were capable of estimating the binding constant; however, the results of MST were 
in greater agreement with the reported values from the literature.  
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Subsequently, human Lf was selected as a target protein, and an experiment was designed to 
estimate the CP20-Lf interaction and evaluate the impact on drug secretion in breast milk as a 
protein-bound molecule during lactation. MST technique proved to be valuable in binding stud-
ies realm. In this study, MST was superior to CE methods and was capable of estimating bind-
ing parameters, While CE methods have been failed to determine Lf protein because of strong 
protein adsorption to the capillary wall. The strong binding affinity between CP20 and Lf as 
shown in MST results reveals that CP20 secretion in breast milk can be predicted.  
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2009-2014 Membership of International pharmaceutical federation 
 
Professional honors & fellowships 
2007 Fellowship program for the clinical instructors, (Ministry of 
Health), Saudi Araibia 
2003 Honored as ideal student (Faculty of Pharmacy candidate) 
from King Saud University 
  
2003 Honored as a leader for non-academic activities in Faculty of 
Pharmacy, King Saud University 
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Training courses & workshops 
• Effective meeting workshop, Grade life program, 6th and 7th November 2017, 
Braunschweig 
• Scientific integrity workshop, Grade life program, 18th and 19th December 
2017, Braunschweig  
• Basic chemometrics course, Euroanalysis 2017, 28th August 2017, Stock-
holm 
• Robust CE method Course, Euroanalysis 2017, 28th August 2017, Stock-
holm 
• Targeted metabolomics for biomarker discovery workshop, MHH, 2nd No-
vember 2016, Hannover  
• Bioanalytics meeting, NanoTemper Technologies, 27th and 28th October 
2016, Muncih 
• Bioanalytics meeting, NanoTemper Technologies, 16th and 17th June 2016, 
Muncih 
• Fundamentals of mass spectrometry course, ISC2014, 13 Septemper 2014, 
Salzburg 
• Bases of chemical safety workshop, chemical safety program, 5th and 6th 
May 2013, Riyadh  
• Strategic planning for the colleges workshop, Knig Khalid University, 13th 
Febreuary 2013, ABHA   
• Cardiopulmonary resuscitation as BLS provider, training course, Saudi Hear 
Association, 2012, Saudi Arabia  
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1. Asmari M., Ratih R., Alhazmia H., El Deeb S., Thermophoresis for char-
acterizing biomolecular interaction, Methods (2018), 146, 107-119. 
DOI: org/10.1016/j.ymeth.2018.02.003 
 
 
2. Asmari M., Michalcova L., Alhazmi H., Zdenek G., El Deeb S., Investiga-
tion of deferiprone binding to different essential metal ions using mi-
croscale thermophoresis and electrospray ionization mass spectrometry, 
Michrochemical Journal (2018), 137, 98-104. 
DOI: org/10.1016/j.microc.2017.10.004 
 
3. Al Bratty M., Alhazmi A. H., Javed A. S., Lalitha G. K., Asmari M., Wölker 
J., El Deeb S., Development and Validation of LC–MS/MS Method for Sim-
ultaneous Determination of Metformin and Four Gliptins in Human Plasma, 
Chromatographia (2017), 80, 891- 899. 
DOI: 10.1007/s10337-017-3288-0 
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Poster 
presentation 
 
 
1. Asmari M., Ratih R., El Deeb S., Label-free microscale thermophoresis for 
the study of lactoferrin-drug interaction, Euroanalysis 2017 in Stockholm, 
28 August -1 Septemper, 2017 (Sweden). 
2. Ratih R., Asmari M., Oner S., El Deeb S., Immobilization of Chondroitin 
Sulfate A into Monolithic Epoxy Column for Chiral Separation, HPLC 2017 
in Prague, June 18-22, 2017 (Czech Republic). 
3. Michalcová L., Asmari M., Glatz Z., El Deeb S., Capillary Electrophoresis-
Frontal Analysis for the characterization of drug-metal binding, CE-2016 in 
Berno, October 16-19, 2016 (Czech Republic). 
4. Asmari M., Kleusch C., El Deeb S., MicroScale thermophoretic investiga-
tion of deferiprone interaction with selected biometals, DPhG (German As-
sociation of Pharmacists) in Munich, October 4-7, 2016 (in Germany). 
5. Uzlu Z., Ule J., Ahmed F., Balaiev I., Asmari M., Eldeeb S., Investigation 
of deferiprone binding to zinc (II) and copper (II) ions for potential chelation 
effect using capillary zone electrophoresis, Internship scientific day TU 
Braunschweig, 10th May, 2016 (Germany). 
6. Asmari M., Alhazmi H., El Deeb S., LC-ESI-MS Study of Iron (III) Com-
plexes with Deferiprone, Analytical Technology Europe in Vienna, March 
15-18, 2016 (Austria). 
7. Asmari M., Alhazmi H., Wölker J., El Deeb S., LC-ESI-MS method devel-
opment and validation for determination of five hypoglycemic agents in 
mixture using monolithic silica column, DPhG (German Association of 
Pharmacists) in Dusseldorf, September 
23-25, 2015 (Germany). 
 
 
 
 
 
 
